

ISSUED TO M/s. _____

S.No.....

NOT TRANSFERABLE



TENDER NO. :- BPPI/DRUG-025/2015

**TENDER FOR SUPPLY OF DRUGS &
MEDICINES**

TO

**Bureau of Pharma Public Sector Undertakings of
India (BPPI)**

For the year 2015-17



BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under the Department of Pharmaceuticals, Govt. of India)

IDPL corporate office Complex, Old-Delhi-Gurgaon Road, Dundahera, Gurgaon 122016

Telephone: 0124-4040759 / 4556751; Fax: 0124-2340370 Website: janaushadhi.gov.in

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)

(SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA)

Regd. Office: Core No. 6, First Floor, SCOPE Complex, Lodi Road, New Delhi-110003

Working Office: IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHERA, GURGAON (HR)

Telephone: **0124-4556751/56**; Fax: **0124-2340370** Website: **janaushadhi.gov.in**

**TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO
BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF
INDIA FOR THE YEAR 2015-2017**

Tender Reference	BPPI/DRUG- 025/2015 Dt. 13.07.2015
Date of commencement of Sale of tender documents	13.07.2015(Monday)
Time and date and place pre-bid meeting	11:00 AM on 22/07/2015 (Wednesday) Bureau of Pharma Public Sector Undertakings of India, IDPL corporate office, IDPL Complex, Old-Delhi -Gurgaon Road, Dundahera, Gurgaon-122016 (Haryana)
Last date and time for receipt of tender documents	04/08/2015 upto 12:00 Noon
Time and date of opening of tender	12:30 PM on 04/08/2015 (Tuesday)
Place of opening of tender	Bureau of Pharma Public Sector Undertakings of India, IDPL corporate office, IDPL Complex, Old-Delhi -Gurgaon Road, Dundahera, Gurgaon-122016 (Haryana)
Address for Communication	Bureau of Pharma Public Sector Undertakings of India, IDPL corporate office, IDPL Complex, Old-Delhi -Gurgaon Road, Dundahera, Gurgaon-122016 (Haryana)

Cost of the Tender Document		Rs. 2,250/- (Inclusive of Tax)
Contact Person for clarification if any		1. Sh. K Chopra, Director (Operations) Phone:- 0124-4040759/4556751 Mob:- 9711003043 Email: opr.janaushadhi@gov.in; kchopra.bppi@gmail.com 2. Mrs. Sanyukta Singh, Assistant (Procurement) Phone:- 0124-4556767 Email:- proc1.bppi@gmail.com

Alternatively, the tender document can be downloaded from the website of BPPI: janaushadhi.gov.in and pharmaceuticals.gov.in. However the cost of tender form needs to be paid by way of demand draft drawn in any nationalized bank in favor of “Bureau of Pharma public sector undertakings of India “payable at Gurgaon/Delhi along with tender document at the time of submission.

TABLE OF CONTENTS

Sl.No.	Description	Page No.
1.	Last Date for receipt of Tender	07
2.	Eligibility Criteria	07
3.	General Conditions	08
4.	Technical Bid – Cover “A”	09
5.	Price Bid – Cover “B”	12
6.	Opening of Cover “A” and Cover “B” of Tender	14
7.	Earnest Money Deposit	14
8.	Other Conditions	15
9.	Acceptance of Tender	16
10.	Security Deposit and Agreement	17
11.	Methodology for placing orders	18
12.	Supply Conditions	20
13.	Logograms	22
14.	Packing	22
15.	Quality Testing	23
16.	Payment Provisions	24
17.	Handling & Testing Charges	26
18.	Liquidated Damages and other penalties	26
19.	Deduction and other penalties on account of Quality failure	27
20.	Blacklisting in the event of withdrawal from the tender, and Non-Adherence to the Quality Standards and supply schedule	28
21.	Saving Clause	31
22.	Resolution of Disputes	31
23.	Appeal	32
24.	Contacting the Purchaser by the Bidder	32
25.	Fraudulent and Corrupt Practices	32
26.	Jurisdiction	35
27.	ANNEXURE-I (Declaration for eligibility in participating the tender)	36
28.	ANNEXURE –II (Bar Coding)	37

29.	ANNEXURE –III (Proforma for Performance Certificate)	42
30.	ANNEXURE –IV (Declaration for acceptance of tender conditions and compliance of GMP)	43
31.	ANNEXURE -V (Annual Turnover Statement)	44
32.	ANNEXURE-VI (Sales Tax Clearance Certificate)	45
33.	ANNEXURE -VII (Declaration for logogram)	47
34.	ANNEXURE -VIII (Details of Manufacturing Unit)	54
35.	ANNEXURE -IX (List of Items quoted)	56
36.	ANNEXURE -X (Check List)	57
37.	ANNEXURE -XI (Details of EMD submitted)	59
38.	ANNEXURE –XII (Notarized Under taking)	60
39.	ANNEXURE -XIII (Details of requirements for Drugs and Medicines)	61
40..	ANNEXURE -XIV (Performance Security Bank Guarantee)	69
41.	ANNEXURE -XV (Agreement format)	70
42.	ANNEXURE -XVI (Packing Specifications)	73
43.	ANNEXURE -XVII (Mandate Form for RTGS)	76
44.	ANNEXURE -XVIII (Break up Details of Landed Price)	78
45.	ANNEXURE -XIX (The Landed Price)	91

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

FOR THE YEAR 2015-17

Jan Aushadhi Scheme is the initiative of Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India launching with the noble objective of making quality generic medicines available at affordable prices for all, particularly the poor and disadvantaged, through specialized outlets called Jan Aushadhi Stores (JAS). In order to enable a focused and institutional approach to implement the Jan Aushadhi Campaign in particular, BPPI was established in December, 2008 under the Department of Pharmaceuticals, Government of India, with the support of all the CPSUs, and identified as the executing agency for JAS Scheme.

The Bureau has been registered as an independent society under the Societies Registration Act, 1860, in April, 2010. BPPI follows the provisions of GFR, 2005 as amended from time to time, the CVC guidelines, and instructions from the Department of Pharmaceuticals.

After varied success in last five years and to give a new thrust to Jan Aushadhi Campaign, a New Business Plan has been worked out. It aims to extend the geographical coverage of the scheme, by opening more than 3000 stores during the 12th Plan Period. It is proposed to channelize efforts to popularize the scheme in a few selected states and ensure availability of the complete basket of medicines at affordable prices.

Tender Inviting Authority – Director (Operations), Bureau of Pharma Public Sector Undertakings of India, IDPL Corporate Office, IDPL Complex, Old-Delhi-Gurgaon Road, Dundahera, Gurgaon -122016 (Haryana) (hereinafter referred as **Tender Inviting Authority** unless the context otherwise requires).

Tender Accepting Authority – CEO, Bureau of Pharma Public Sector Undertakings of India, (hereinafter referred as **BPPI** unless the context otherwise requires)

Tender Inviting Authority invites **Tender for the supply of Drugs and Medicines to BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, for the year 2015-2017.**

1. LAST DATE FOR RECEIPT OF TENDERS.

(a) Sealed Tenders [in two separate covers {Technical bid (Cover “A”) and price bid Price Bid (Cover “B”)}] will be received **till 12:00 Noon upto 04/08/2015(Tuesday)** by the Tender Inviting Authority, Bureau of Pharma Public Sector Undertakings of India, IDPL corporate office, IDPL complex, Old-Delhi-Gurgaon Road, Dundaheera, Gurgaon -122016 (Haryana) for the year 2015-17.

(b) The price bid shall be valid for a period of 120 days from the date of opening of Cover-A (Technical Bid). Prior to the expiry of the bid validity, the Tender Inviting Authority may request the Tenderers to extend the bid validity for further period as deemed fit on their original quoted prices and all terms & conditions. However, BPPI reserves the right to place purchase orders at the quoted rate till such period.

2. ELIGIBILITY CRITERIA

(a) Tenderer shall be a manufacturer having valid own drug manufacturing unit duly licensed by licensing authorities with valid GMP certificate/WHO Certificate or direct importer holding valid import license. Distributors/Suppliers/Agents are not eligible to participate in the Tenders. Loan licensees are allowed provided the average annual turnover of bidding company should be at least Rs. 100 Crores for last 3 years and the average annual turnover of Host Firm (actual manufacturer) should be minimum Rs. 10 crores during the last 3 years.

(b) Average Annual turnover in the last three years i.e. 2012-2013, 2013-2014 and 2014-15 shall not be less than **Rs. 10 Crores**. For loan licensees, average annual turnover should be at least 50 crores in last 3 years.

(c) Tender should not be submitted for the product(s) for which the firm / company has been blacklisted/debarred/de-registered by any State Government / Central Government / its Drug procurement agencies due to quality failure of the drugs ***at the time of submission of tender documents.***

(d) The Company/Firm which has been blacklisted/debarred/de-registered by any State Government/Central Government / its Drug procurement agencies due to quality failure of the drugs supplied should not participate in the tender during the period of blacklisting/debarred/de-registration ***at the time of submission of tender documents.***

(e) (i) The Tenderer should give a notarized affidavit that they have not been black listed/debarred/de-registered due to quality failure for the quoted product /firm by any State Government / Central Government / its Drug procurement agencies. (Notarized affidavit as per **ANNEXURE-I**) ***at the time of submission of tender documents.***

(ii) During the validity of the tender if the firm / Company is blacklisted/debarred/de-registered by any State Government / Central Government / its Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to BPPI alongwith relevant authentic document by the tenderer firm/ company within one month.

(f) Tenderer are required to incorporate bar codes as per GS1 standards at various packaging levels (primary, secondary and tertiary) (**ANNEXURE – II**)

3. GENERAL CONDITIONS.

(i) The tender document shall be download from the websites **janaushadhi.gov.in**; **pharmaceuticals.gov.in** and CPP portal i.e. **eprocure.gov.in**. However the cost of tender form needs to be paid by way of demand draft drawn in any nationalized bank in favor of “Bureau of Pharma Public Sector Undertakings of India” payable at Gurgaon/Delhi along with the tender. In case demand draft towards the cost of tender is not submitted along with tender, their bid shall be rejected straightaway.

(ii) All tenders must be accompanied with Earnest Money Deposit as specified in Clause 7 of the Tender document. The bid received without requisite amount of EMD will be summarily rejected.

(iii) Tenders will be opened in the presence of Tenderers/authorized representatives who choose to attend on the specified date and time. They should bring letter of authority authorising to attend tender opening on the printed letter head of the company.

(iv) (a) At any time prior to the last date of submission of Tender, Tender Inviting Authority may, for any reason, whether on own initiative or in response to a clarification requested by a prospective Tenderer, may modify the condition in Tender documents by an amendment. All the prospective Tenderers who have purchased the tender document will be notified of the amendment in writing and that will be binding on them. In order to provide reasonable time to take the amendment into account in preparing their bid, Tender Inviting Authority may at discretion, extend the date and time for submission of tenders.

(b) Any person who has downloaded the tender document should watch for amendment, if any, on the website **janaushadhi.gov.in**; **pharmaceuticals.gov.in** and CPP portal i.e. **eprocure.gov.in** for which BPPI will not issue any separate communication to them.

(v) Interested eligible Tenderers may obtain further information in this regard from the office of the Tender Inviting Authority on all working days between 10:00 AM and 5:00 PM.

(vi) Certain products are reserved for purchase from Central Public Sector Undertakings (CPSU's). Orders for these items will be first placed with CPSU's.

4. TECHNICAL BID - COVER "A"

4.1. The Tenderer should furnish the following documents in a separate cover hereafter called "**Cover A**". **(All the documents submitted should be signed and sealed by the Tenderer in each page and photocopies of the documents should be attested by the Tenderer/authorised person.**

(a) Earnest Money Deposit, shall be as indicated in Clause 7 of the tender document in the form of **Bankers Cheque or Demand Draft** favouring "Bureau of Pharma Public Sector Undertakings of India " , payable at Gurgaon/Delhi . EMD in any other form like *cheque/cash/postal order* etc. **will not be accepted.**

(b) Documentary evidence for the constitution of the Company/Firm such as Memorandum and Articles of Association, Partnership deed, Permanent Registration Number etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor. The list of present Directors in the Board of the Company duly certified by a Company Secretary of the Company/Practicing Company Secretary / Chartered Accountant to be furnished.

(c) The Tenderer should furnish self attested photocopy of valid drug Manufacturing Licence for the product, duly approved by the Licensing Authority for each and every product quoted as per specification in the tender. The licence must have been duly renewed up to date and the items quoted shall be clearly highlighted in the licence. Original documents should be produced for verification when demanded. However, if renewal application for manufacturing licence has been filed, copy of same duly receipted by drug authorities must be enclosed along with the validity certificate from state licencing authority (SLA)

(d) Self attested photocopy of import license (in Form 10 with Form 41), as per Rule 122A of the Drugs and Cosmetics Act 1940, if the product is imported should be furnished. The licence must have been renewed up to date. A copy of a valid licence for the sale of Drugs imported by the firms issued by the State Licensing Authority shall be enclosed. Original documents should be produced for verification when demanded.

(e) The instruments such as power of attorney, resolution of board etc., authorizing an officer of the Tenderer should be enclosed with the tender duly signed by the Authorized signatory of the Company/Firm and such authorized officer of the Tenderer should sign the tender documents.

(f) Authorization letter nominating an officer of the Tenderer on the printed letter head of the company to transact the business with the BPPI to be furnished.

(g) **MARKET STANDING CERTIFICATE (MSC) ISSUED BY THE STATE LICENSING AUTHORITY UNDER generic or brand name as a Manufacturer for each product quoted in the tender for a minimum 3 years (Certificate should be enclosed with list of items). In case of direct importer, evidence for importing the said items such as bill of landing, bill of entry and certificate of analysis are to be produced. MSC issued under brand name or under generic name (by the state licensing authority) will also be accepted but supplies will be accepted only in generic name.**

(h) Performance statement of manufacture/import to establish market standing as per format in **ANNEXURE- III**. Marketing certificate for 3 years for the product/s manufactured at two locations/factories of same manufacturer (in case if the manufacturer in the new location do not complete 3 years at time of tender application) will also be accepted.

(i) Non-conviction Certificate issued by the licensing authority of the State certifying that the firm/company has not been convicted. The certificate should not be more than 6 months old at the time of submission of technical bid.

(j) Valid Good Manufacturing Practices Certificate (GMP) as per Schedule-‘M’ (for manufacturers only)/WHO certificate issued by the Licensing Authority. The Tenderer shall also furnish a notarized declaration in the format given in **ANNEXURE-IV** declaring that the Tenderer complies with the requirements of GMP (as per Schedule-‘M’). In case of Imported drugs, labels and product literature of all quoted product(s) must be submitted with WHO-GMP/certificate which is at par with WHO-GMP issued by exporting countries like U.S. FDA etc/COPP certificate of their Principal Manufacturing company/firm.

(k) Annual turnover statement for 3 years i.e., 2012-2013, 2013-2014 and 2014-15 should be furnished in the format given in **ANNEXURE-V** duly certified by the chartered Accountant.

(l) Copies of the Annual reports including the Balance Sheet and Profit and Loss Account for the last three years i.e. 2012-2013, 2013-2014 and 2014-15 duly certified by the Chartered Accountant.

(m) a. Sales Tax Clearance certificate as on 31.03.2015 (as per form attached in **ANNEXURE-VI**).

b. Latest Income tax assessment orders/returns filed are to be attached.

(n) (i) Undertaking (as in the proforma given in **ANNEXURE-VII**) for embossment of logo on strip of tablets, capsules, on labels of vials, Ampoules, bottles, tubes etc. as the case may be, and for supply of tablets/capsules in strips as per conditions specified under Clause 13 herein, notarized by the Notary Public.

(ii) Undertaking (as in the proforma given in **ANNEXURE-VII (A)**) for affixing the Jan Aushadhi logo on the Secondary/Primary packing for the imported items along with Brand/Trade names.

(o) The details containing the name and address of the manufacturing premises / importing unit where the items quoted are actually manufactured should be given as per the format in **ANNEXURE-VIII** along with exact address of registered/Corporate office.

(p) Documents, if any, to show that the manufacturing unit/importer has been recognized by any other Indian / International Standard Organizations etc. as applicable.

(q) The loan license bidder are required to submit all the documents as per tender requirements for own manufacturing unit plus 10 crores average annual turnover of host company/actual manufacturer.

(r) List of items quoted (The name & Drug code of the Items quoted should be Furnished and **the rate of those items should not be indicated in this list**), as shown in the **ANNEXURE-IX** should be given in duplicate.

(s) A Checklist (**ANNEXURE- X**) indicating the documents submitted with the tender document and their respective page number shall be enclosed with the tender document. The documents should be serially arranged as per this **ANNEXURE- X** and should be securely tied or bound. If a company/firm has two or more separate manufacturing units at different sites / States, which are not separate entities then the company will be allowed to submit only one tender for all units but necessary document regarding separate manufacturing units will be submitted as a separate set with the same tender. However one bidder will be allowed to submit only one offer for one product.

(t) The tender document should be signed by the authorized official of the Tenderer in all pages with office seal.

(u) All the documents enclosed with the tender document should also be signed by the authorized official of the Tenderer.

4.2. The all documents indicated above should be kept and sealed in a separate Cover Superscribed as "TECHNICAL BID - COVER "A" – TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA FOR THE YEAR 2015-2017 DUE ON **04/08/2015** at 12:00 NOON. AND ADDRESSED TO THE TENDER INVITING AUTHOURITY, BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA ,IDPL CORPORATE OFFICE, IDPL COMPLEX, OLD – DELHI- GURGAON ROAD, DUNDAHERA, GURGAON- 122016 (HARYANA).

5. PRICE BID - COVER "B"

5.1. Cover "B" contains the Price Bid of the Tenderer.

(i) Bid should be computer printed. The correction should be avoided. However, in exigency, it shall be certified with full signature by the Tenderer, failing which the bid will be treated as ineligible. Corrections done with correction fluid will not be accepted.

(ii) Each page of the price bid should be duly signed by the Tenderer affixing the office seal.

(iii) (a) The Tenderer shall fill in the rate in the **ANNEXURE-XVIII** and **ANNEXURE-XIX** for the items quoted and also in excel sheets (supplied with tender document) and such filled in **ANNEXURE-XVIII** and **ANNEXURE-XIX** in soft copy should be submitted in pen drive or compact disc (CD).

(b) The Tenderers who have downloaded Tender document shall also download excel files of **ANNEXURE-XVIII** and **ANNEXURE-XIX** and soft copies of such filled in **ANNEXURE-XVIII** and **ANNEXURE-XIX** should be submitted in pen drive or compact disc.

(iv) **Determination of L1 bidder:** In determining the lowest evaluated price, the rate quoted per unit landed price as indicated in column No. 7 of the **ANNEXURE-XIX** shall be taken into consideration.

(v) The rate quoted in column 7 of **ANNEXURE -XIX** should be for a unit and for the given specification. **The rates quoted in paisa are to be in 2 digits.** The Tenderer is not permitted to change/alter specification or unit size given in the **ANNEXURE- XIII and ANNEXURE XVIII**.

(vi) The Tenderer is required to furnish the break up details of landed price in **ANNEXURE -XVIII**.

(vii) The rate quoted in column 7 of **ANNEXURE -XIX** and in column 9 of **ANNEXURE XVIII** should be one and the same.

(viii) The details of products rates and manufacturing capacity (for each item individually) given in **ANNEXURE -XIX** should be entered clearly given along with the tender.

EXCISE DUTY-

(ix) The tenderers must indicate the rate/quantum of Excise duty applicable and payable by them irrespective of the fact whether the quoted prices are inclusive or exclusive of Excise Duty. If a tenderer states that the Excise duty is NIL/EXEMPTED, he must intimate the basis for the same and also confirm that no Excise Duty will be charged by him under any circumstances.

(x) In case, no information about excise duty is given, it will be taken as inclusive.

ST/CST/VAT

(xi) The tenderers must indicate the rate/quantum of ST/CST/VAT applicable and payable by them irrespective of the fact whether the quoted prices are inclusive or exclusive of Excise Duty.

5.2. The Tenderers shall submit duly signed **ANNEXURE-XVIII** and **ANNEXURE-XIX** in a sealed cover Super scribed as **“PRICE BID COVER “B” –**

TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO BPPI FOR THE YEAR 2015-2017”.

The "Cover-B" should also be addressed to the **TENDER INVITING AUTHORITY, BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, IDPL CORPORATE OFFICE, IDPL COMPLEX, OLD- DELHI- GURGAON ROAD, DUNDAHERA, GURGAON-122016(HARYANA)**

5.3. Two sealed covers {Technical bid (Cover “A”) {Refer Clause No.4.2} and Price Bid (Cover “B”)} {Refer clause (5.2) } shall be placed in a separate cover which shall be sealed and Superscribed as

“TENDER FOR THE SUPPLY OF DRUGS AND MEDICINES TO “BPPI” FOR THE YEAR 2015-2017 DUE ON 04/08/2015 AT 12.00 NOON and addressed to the

TENDER INVITING AUHORITY, BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, IDPL CORPORATE OFFICE, IDPL COMPLEX, OLD- DELHI- GURGAON ROAD, DUNDAHERA, GURGAON-122016(HARYANA), which shall be submitted within the date and time as specified in Clause 1(a).

5.4. If the last date for submission of Tender is declared holiday, the tenders may be submitted on the next working day upto 12.00 A.M.

6. OPENING OF COVER “A” AND COVER “B” OF TENDER

6.1 Only authorized official as indicated in Clause 4.1. (f) are entitled to be present at the time of opening of Technical Bid - Cover “A” of the tender submitted by them.

6.2 Tenderers, who are found eligible on satisfying the criteria for technical evaluation and inspection, will only be invited to be present at the time of opening of Price Bid - Cover “B” of the tender.

7. EARNEST MONEY DEPOSIT

7.1. The Earnest Money Deposit referred to under Clause 3(iv) & 4.1(a), shall be **Rs. 1 lakh. The Earnest Money Deposit shall be paid in the form of Bankers Cheque or Demand Draft in favor of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, payable at Gurgaon/Delhi.(ANNEXURE-XI).**

7.2.(i) The tender submitted without sufficient EMD will be summarily rejected.

(ii) The Earnest Money Deposit will be refunded to the successful bidders within 30 days from the date of signing the contract agreement and on the deposit of Security Deposit.

(iii) The Earnest Money Deposit (EMD) of the unsuccessful bidders will be returned after finalization of tender/signing of agreement with eligible bidder.

(iv) The Earnest Money Deposit (EMD) will be forfeited, if the tenderer withdraws his bid any time after opening of price bid / non execution of agreement /undertaking within the period prescribed.

(v) The Earnest Money Deposit (EMD) will be forfeited, in case of the lowest bidder, fails to execute the contract agreement and / or deposit the security Deposit within the stipulated time(**ANNEXURE-XII**).

(vi) Tenderer may be exempted from the payment of EMD, provided that valid **registration** certificate from NSIC duly self attested is produced **for the product for which bidder has submitted quotation..**

(vii) State PSUs are exempted from the payment of EMD.

8. OTHER CONDITIONS

8.1.(i) The details of the required drugs, medicines, etc., are shown in **ANNEXURE - XIII**. *The tender quantity mentioned herein is not a fixed procurement quantity and it is only a tentative requirement and may be increased or decreased* by the BPPI, at its discretion, depending on its actual need. Though the tentative quantity is indicated in the agreement, the BPPI, will confirm the actual requirement then / there through purchase order/orders. The tenderers shall supply the drugs only on the basis of the purchase order issued time to time within validity of contract period by the BPPI. Any supply without a valid purchase order will not be acceptable by BPPI and the BPPI shall not be responsible for any loss on this account.

(ii) However, once the purchase order/orders is/are issued by the BPPI, the tenderer shall not renege from the commitment of supplying the quantity mentioned in the agreement / undertaking.

(iii) The rates quoted shall not be varied with the ordered quantity during the full contract period.

8.2. Tender has been called for in the **generic name of drugs**. The Tenderers should quote the rates for the generic products only. The composition, strength and packing of each product should be as per specifications given in **ANNEXURE -XIII**. Any variation, if found, will result in rejection of the tender. However the imported/combination drugs are allowed to quote in trade / brand name.

8.3. Rates (inclusive of Customs duty, bar coding, transportation, insurance—and any incidental charges, but exclusive CST/VAT (Sales Tax) and excise duty) should be quoted for each of the required drugs, of medicines etc., separately on door delivery basis according to the unit ordered. Tender for the supply of drugs, medicines, etc. with cross conditions like “AT CURRENT MARKET RATES” shall not be accepted. Handling, clearing, transport charges etc., will not be paid separately. The delivery should be made as stipulated in the purchase order placed with Tenderers.

8.4. Each bid must contain not only the unit rate but also the total value of each item quoted for supply in the respective columns. The aggregate value of all the items quoted in the tender shall also be furnished.

8.5. The price quoted by the tenderers shall not, in any case exceed the DPCO controlled price, if any, fixed by the Central/State Government, the Maximum Retail Price (MRP) and the selling price of the tenderer. Tender Inviting Authority at its discretion, may exercise, the right to revise the price at any stage so as to conform to the controlled price or MRP or the selling price of the tenderer as the case may be. This discretion will be exercised without prejudice to any other action that may be taken against the Tenderer.

8.6. The rates quoted and accepted will be binding on the Tenderer for the full contract period of two years and any increase in the price will not be entertained till the completion of this contract period. Accordingly this clause will be applicable for all orders placed during the contract period.

8.7. No Tenderer shall be allowed at any time and on any ground, whatsoever it may be, to claim revision or modification in the rates quoted by them. Representation to make correction in the tender documents on the ground of Clerical error, typographical error, etc., committed by the Tenderers in the Bids shall not be entertained after submission of the tenders. Cross Conditions such as “SUBJECT TO AVAILABILITY”, “SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED” etc., will not be entertained under any circumstances and the tenders of those who have mentioned such conditions shall be treated as incomplete and accordingly the Tender will be summarily rejected.

8.8. Supplies should be made directly by the tenderer and not through any other Agency / Dealer / Distributors.

8.9. The Tenderer shall allow inspection of the factory at any time after the opening of technical bid and during the entire contract period by a team of Experts/Officials nominated by the Tender Inviting Authority for the purpose. The Tenderer shall extend necessary cooperation to such team in inspection of the manufacturing process, quality control measures adopted etc., in the manufacture of the items quoted. If Company/Firm does not allow for any such inspection, their tenders will be rejected. If any such situation arises after placement of contract, the same shall be cancelled at the firm’s risk cost.

8.10 “MRP inclusive of all taxes” is to be printed on each unit/label. MRP will be intimated to successful bidders at the time of placing purchase orders.

9. ACCEPTANCE OF TENDER

9.1. Evaluation of the tender and determination of the L1 rate (Lowest rate) will be done on the basis of rate per unit landed price as mentioned in column 7 of **ANNEXURE-XIX** and column 9 of **ANNEXURE-XVIII**. Negotiation if required will be done at our premises and the same will be done strictly as per Central Vigilance Commission guidelines.

9.2. BPPI reserves the right to accept or reject the tender for the supply of all or any one or more items of the drugs tendered for in a tender without assigning any reason.

9.3. BPPI or its authorized representative(s) has/have the right to inspect the manufacturing premises of Tenderers, before accepting the rate quoted by them or before releasing any purchase order(s) or at any point of time during the continuance of tender and also has the right to reject the tender or terminate/cancel the purchase orders issued and/or not to place further order, based on adverse reports brought out during such inspections.

9.4. The acceptance of the tenders will be communicated to the lowest Tenderers in writing.

10. SECURITY DEPOSIT AND AGREEMENT

10.1 Security Deposit:

On being informed about the acceptance of the tender and at the time of signing the Agreement, the Tenderer shall pay the Security Deposit @ 5% of the value of order in the form of ***Demand Draft or irrevocable Bank Guarantee*** in favour of Bureau of Pharma Public Sector Undertakings of India from any scheduled Bank. In case the Security Deposit is paid in form of Bank Guarantee, the bank guarantee shall be valid for a period beyond 3 months of the validity of the contract. The format of Bank Guarantee is at **ANNEXURE-XIV**.

10.2. The Tenderer shall execute an agreement on a non- judicial stamp paper of value of Rs.100/- (stamp duty to be paid by the Tenderer) within 15 days from the date of the intimation from BPPI informing that his tender has been accepted. The Specimen form of agreement is available in **ANNEXURE-XV**.

10.3. The Tenderer shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons what so ever.

10.4. All notices or communications relating to and arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Tenderer if delivered to him or left at the premises, places of business or abode as provided by the tenderer.

10.5. If the lowest Tenderer fails to execute the agreement and/or to deposit the required security deposit within the time specified or withdraws the tender, after the intimation of the acceptance of the tender or owing to any other reasons to undertake the contract, the contract will be cancelled and the Earnest Money Deposit deposited by the tenderer along with the tender shall stand forfeited by the BPPI and the firm will also be liable for all damages sustained by the BPPI apart from blacklisting and other penal actions.

10.6. The security deposit of supplier will be returned by BPPI only after the supplier has given undertaking to replace such medicines and indemnify BPPI against any losses on account of quality parameters.

11. METHODOLOGY FOR PLACING ORDERS

For the above purpose the following procedures will be adopted

(a) After the conclusion of Price Bid opening (Cover B), the rates offered by tenderers for each product are evaluated and lowest acceptable rate (L1 Rate) arrived at is declared and that tenderer is informed.

(b) The Successful Tenderer is eligible for the placement of Purchase Orders only after depositing the required amount as Performance Security and on execution of the agreement.

(c) If two or more than two Tenderer's are declared as lowest suppliers for the same item(s), such Tenderers shall execute necessary agreement as specified in the Tender Document on depositing the required amount as Performance Security and on execution of the agreement such Tenderer's are eligible for the placement of Purchase Orders for such item(s) for which they are declared as lowest. Placement of order shall be shared equally amongst these bidders subject to their manufacturing capacity.

(d) In the case of purchase of goods where the quantity offered at the lowest price is less than the total quantity required, the BPPI may, after placing orders with the lowest evaluated Tenderer for the entire quantity offered by such Tenderer subject to his ability to supply, require all the other eligible Tenderers who participated in the tender and offered a price higher than that offered by the lowest evaluated Tenderer, to submit sealed offers of the quantity they would be willing to supply at the price quoted by the lowest evaluated Tenderer, and thereafter place orders for the remaining required quantity with all those who match the lowest evaluated price such that those who bid lower prices in the original tender get a higher priority for supply.

(e) If a supplier fails to execute 3 successive supply orders successfully, their security deposit shall be FORFEITED and their bad performance shall be kept in record of BPPI for future dealing as considered appropriate by BPPI with stipulated delivery period including L.D. Period.

(f) Notwithstanding anything contained in para (e) above, the supplier, after committing the default in supply either partly or fully, can inform the BPPI about his willingness to execute the Purchase Order during the tender period. The BPPI at discretion may consider the willingness of the supplier on merit. However, such supplies will be subjected to the levy of Liquidated Damages, unexecuted fine and other penalties as stipulated in the tender document, agreement and purchase order.

(g) The supplier shall start supply of the Drugs/Medicines required by BPPI at Central Ware House (CWH), Gurgaon within the stipulated period.

(h) The Drugs/Medicines supplied in excess of the ordered quantity shall not be accepted and the supplier shall take back the excess at their cost. BPPI will not be responsible for the loss to the supplier and will not entertain any demand/claim.

(i) The supplier shall supply the Drugs/Medicines at the CWH, Gurgaon along with copy of Purchase order, copy of test reports and 3 original copies of Invoice. No payment will be processed without test reports.

(j) The supplier shall take utmost care in supplying the quality Drugs/Medicines and ensure that the batch number mentioned in the packages of the Drugs/Medicines tally with the batch number mentioned in the Invoice produced to BPPI for payment. Also the supplier shall ensure the quantity relevant to the Batch Number of the Drugs/Medicines is mentioned in the invoice.

(k) It is the duty of the supplier to supply Drugs/Medicines at the CWH Gurgaon and supply shall conform to the conditions mentioned in the provisions of tender documents, viz., logo, nomenclature, specification etc.,

(l) Subject to para (l) above, BPPI will process the invoices submitted by the supplier and the payments against supply will be made, within 30 days from the date the Drugs/Medicines supplied has been declared of STANDARD QUALITY, by the Empanelled laboratory of BPPI subject to various terms and conditions of the tender.

(m) Subject to the conditions mentioned in the Purchase Order, Tender Document, Agreement executed by the supplier and here under, the Supplier is entitled for the payment against supply. In case of any discrepancy in levy of LD, Penalty, Unexecuted Fine, Short Passing of Bills, such discrepancy shall be intimated within 30 days from the date of receipt of payment, failing which BPPI will not entertain any claim thereafter.

(n) BPPI reserves the right to place upto 50% additional purchase order of the quantities as contracted within validity of contract.

12. SUPPLY CONDITIONS

12.1. Purchase orders will be issued to the Tenderer(s) at the discretion of the BPPI as per actual requirements. All the supplies shall be received at the central warehouse at Gurgaon.

12.2. Within 3 days from the receipt of purchase orders the Tenderer should inform BPPI through fax and mail the confirmation for the receipt of the purchase order.

12.3. The Tenderer should also fax and mail the details of supply dates as specified in Annexure, to BPPI within 7 days from the receipt of the purchase order.

12.4. (a) For the first purchase order, the supplier must supply the ordered quantity CWH Gurgaon within 60 days from the date of Purchase Order.

(b) For Subsequent purchase orders, the supplier shall complete the supply within 45 days from the date of purchase order at the destinations mentioned in the purchase order.

(c) If the above day for 12.4 (a) & (b) above happened to be a holiday for BPPI, the supply should be completed by 5.00 PM on the next working day.

(d) In case of Non- execution of the order, BPPI reserves the right to place purchase orders (partially/fully) on alternate source at the risk and cost of the default tenderer(s) without any notice/Information.

(e) If the Tenderer fails to execute the supply within the stipulated time, the BPPI is at liberty to make alternative arrangement for purchase of the items for which the Purchase orders have been placed, from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the defaulted supplier and in such cases the BPPI has every right to recover the cost and impose Liquidated Damages as mentioned in Clause 18.

(f) The supplier may continue the supply of unexecuted quantity after 60th day in case of 12.4(a) above and after 45th day in case of 12.4(b) above, however Liquidated Damages as specified in clause 18.1 and 18.2 of the tender conditions will be levied on the quantity supplied after the 60th day and 45th day respectively. However no supplies will be normally accepted after 5 PM of 90th day from the date of Ist Supply order and 75th day from the date of issue of the subsequent purchase order and the purchase order shall be cancelled at the risk and cost of the supplier.

12.5. Supplier shall complete the earliest pending purchase order before commencing the supply of subsequent purchase orders.

12.6. The supplied medicines and Drugs (covered in SCHEDULE “P” of Drugs and Cosmetics Act) should have the prescribed potency throughout the shelf life period as prescribed in the Drugs and Cosmetics Act 1940 and rules there under and in relevant Pharmacopoeias.

12.7. The Tenderer must submit an Analysis report for every batch of drug along with invoice. In case of failure on part of the supplier to furnish such report, the batch of drugs will be returned back to the suppliers and he is bound to replenish the same with Govt. approved lab test report. The Drugs and medicines supplied by the successful Tenderer shall be of the best quality and shall comply with the specifications, stipulations and conditions specified in the tender.

12.8. Tenderer should supply the product, within 2 months from the date of manufacture of that product. Products beyond 2 months from the date of manufacture shall not be accepted. For example product having manufacturing of April 2015 must be supplied before June 30, 2015. For sterile products having shelf life of 18 months or more, products within 90 days (3 months) from date of manufacture will be accepted.

For imported products, 75% of shelf life should be available at time of supply.

12.9. The order stands cancelled at the end of 90th day from issue of Ist Purchase order and 75th day from the issue of the subsequent purchase order after levying penalty on the value of unexecuted order as specified under Clause 18.3. Further, the Tenderer shall also be liable to pay other penalties as specified under Clause 18. Security Deposit of such suppliers against the contract/agreement shall also be forfeited. Their tender/offer against future tender of BPPI shall not be considered keeping in view of bad performance in previous contract/agreement.

12.10. If at any time the Tenderer has, in the opinion of the BPPI delayed the supply of drugs due to one or more reasons related to Force Majeure events such as riots, mutinies, wars, fire, storm, tempest or other exceptional events at the manufacturing premises, the time for supplying the drugs may be extended by the BPPI at discretion for such period as may be considered reasonable. However such extension shall be considered only if a specific written request is made by the Tenderer within 10 days from the date of occurrence of such event with necessary documentary evidence. The exceptional events does not include the Scarcity of raw material, Increase in the cost of raw material, Electricity failure, Labour disputes/Strikes, Insolvency, and Closure of the Factory/Manufacturing unit on any grounds etc.

12.11. The supplier shall not be liable to pay LD and forfeiture of security deposit for the delay in executing the contract on account of the extension of supply period on the ground of force majeure events.

13. LOGOGRAMS

Logogram means, wherever the context occurs, the design as specified in **ANNEXURE-VII. The name of the drug shall be mentioned in English and Hindi.**

13.1. Tenders for the supply for Drugs and medicines etc., shall be considered only if the Tenderer gives an undertaking that the product(s) will be prepared as per the specifications such as strength, minimum size and packed with appropriate size of the strips/blisters/bottles/tubes etc as per the design enclosed as per **ANNEXURE -VII&VII -A.**

13.2. All tablets and capsules have to be supplied in packing as specified in product list (Annexure ix) and shall also conform to Schedule P1 of the Drugs & Cosmetics Act & Rules 1945, wherever it applies. Affixing of stickers and rubber stamps shall not be accepted and supplies will be returned back at supplier's cost.

13.3. Vials, Ampoules (more or equal than 5 ml) and Bottles containing the items tendered for should also carry the printed Jan Aushadhi logogram of proportionate size.

13.4. Failure to supply Drugs etc., with the printed logogram of proportionate size will be treated as breach of the terms of agreement / violation of tender conditions. The purchase order shall be cancelled at the risk and cost of the supplier. However if such failure continuous despite notice, will be viewed as a serious lapse and initiate blacklisting of the supplier.

Tenderers who are not willing to agree to conditions above will be summarily rejected.

14. PACKING

14.1. The drugs and medicines shall be supplied in the package specified in **ANNEXURE - XIII** and **ANNEXURE -XVI** and the package shall carry the logograms of proportionate size specified in **ANNEXURE –VII, VII -A.** Non affixing of logograms will be treated as violation of tender conditions and fine will be deducted from the amount payable as per condition in Clause 18.5

14.2. The minimum size of each tablet should be 6.4 mm in diameter and the minimum size of the blister packing and strip packing should be 70mm x 30 mm and 50mm x 130mm respectively. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5.

14.3. The packing in each carton shall be strictly as per the specification mentioned in **Annexure-XVI.** The outer carton should be of white board with a minimum of 300 GSM with **Gloss laminated/UV varnished** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with white board of 350 GSM. Failure to comply with

this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5. Storage conditions must be indicated on outer label.

14.4. The cap of bottle preparations should not carry the name of the supplier.

14.5. The labels in the case of Injectable preparations should clearly indicate whether the preparations are meant for Intravenous (IV), Intra Muscular (IM), Intra Dermal (ID), Subcutaneous (SC) administration etc.

14.6. It should be ensured that only firsthand virgin packaging material of uniform size, including bottle and vial, is used for packing.

14.7. All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia.

14.8. Packing should be able to prevent damage or deterioration during transit.

14.9. In the event of items of drugs supplied found to be **not as per specifications in respect of their packing and logogram**, the BPPI is at liberty to make alternative purchase of the items of drugs and medicines for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier. In such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 18 & 19.

14.10. Designs of packaging with the logograms shall be subject to approval by BPPI within 7 days of receipt of the same from the supplier, as per the specifications. In case of failure of BPPI to do so, the supplier may go ahead with the design as per the specification in **ANNEXURE XIII and XVI**.

15. QUALITY TESTING

15.1. Samples of supplies from each batch will be chosen at the point of despatch or receipt of supply or distribution/storage points for testing at discretion of BPPI. The samples will be sent to different laboratories including Government Drugs Testing Laboratory for testing as decided by the BPPI. Handling and testing charges will be deducted by BPPI for the above purpose, as specified in Clause 17.

15.2. The Drugs shall have the active ingredients at the prescribed level as indicated in official compendiums throughout the shelf life period of the drug. The samples will be drawn periodically throughout the shelf life period and if found “Not of Standard Quality”, the cost of entire batch paid will be recovered whether consumed fully/partially. Also action will be initiated for blacklisting as per clause No.19 irrespective of the period of supply. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be “Not of Standard Quality” or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.

15.3. In the event of the samples of Drugs and medicines supplied fails in quality tests or found to be not as per specifications, the BPPI is at liberty to make alternative purchase of the items of drugs and medicines for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier and in such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 19.

15.4. The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the BPPI. In case of any complaint in the field, the B.M.R/B.P.R for the particular batch of the product(s) supplied shall be produced when demanded.

15.5. The products should conform to the standards of IP/BP/USP/EP/JP as the case may be. In case the product is not included in the any of the said compendiums, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing. For imported drugs, respective Country’s Pharmacopeial standards shall be acceptable (even if the product is official in IP).

15.6. The case of admixture of drugs will be treated as a violation of tender conditions and fine will be levied as per clause 19. If such lapses happens more than twice in a tender period such cases will be treated as “Misbranded Drugs”.

16. PAYMENT PROVISIONS

16.1. No advance payments towards costs of drugs, medicines etc., will be made to the Tenderer.

16.2. Payments towards the supply of drugs and medicines will be made within 60 days from the date of receipt of goods, strictly as per the tender terms and condition. The payment will be made either by means of a/c payee Cheque or through RTGS (Real Time Gross Settlement System)/Core Banking/NEFT. The Tenderer shall furnish the relevant details in original (**ANNEXURE -XVII**) to make the payment through RTGS/Core Banking/NEFT.

16.3. All bills/Invoices should be raised in triplicate and in the case of excisable Drugs and Medicines, the bills should be drawn as per Central Excise Rules in the name of Bureau of Pharma Public Sector Undertakings of India. IDPL Complex, Dundaheera, Gurgaon 122016 or in the name of any other authority as may be designated.

16.4. (i) Payments for supply will be considered only after supply of minimum 50% of Drugs ordered in the individual Purchase Order PROVIDED reports of Standard Quality on samples testing are received from Government Analyst or Approved Laboratories of BPPI

(ii) However, in case of cancellation of a particular purchase order due to failure in delivery, payment for part supplies less than 50% of the purchase order quantity on the date of cancellation of the purchase order may be considered for release of payment subject to the following:

(a) If the Tenderer have supplied at least 50% of the quantity ordered in the subsequent purchase order within 60 days from the issue of such purchase order.

(b) If further purchase order is not placed with the supplier due to any reason, not attributable to the supplier, the amount eligible will be paid within 60 days from the date of last supply.

(c) The payment for part supply as mentioned above will subject to the deduction of liquidated damages, penalty towards unexecuted quantity, risk and cost etc., as per the tender conditions.

16.5. If at any time during the period of contract, the price of tendered items is reduced or brought down by any law or Act of the Central or State Government or by the Tenderer himself, the Tenderer shall be bound to inform the BPPI immediately about such reduction in the contracted prices. Tender Inviting Authority is empowered to unilaterally effect such reduction as is necessary in rates in case the Tenderer fails to notify or fails to agree for such reduction of rates.

16.6.(a) In case of any increase or decrease in the taxes, such as excise duty, customs duty, sales tax, VAT etc., after the date of submission of tenders and during the tender period, such variation in the taxes will be to the account of the BPPI. For claiming the additional cost on account of the increase in taxes, the Tenderer should produce the proof of having paid additional amount on this account on the goods supplied to BPPI from the concerned Excise authorities and also must claim the same in the invoice separately. However the basic price structure and the price of the Drugs approved under the tender shall not be altered. Similarly if there is any reduction in the taxes and statutory levies as notified by the Govt., after the date of submission of tender, the Tenderer will be paid based on the unit rate worked out on the basis of the reduced taxes/statutory levies without any change in the basic price or the price structure of the drugs approved under the tender.

Any increase or decrease in taxes and statutory levies will be considered based on the notification issued by the Government.

However, if the firm supplies after originally stipulated Delivery period, increase in Excise duty/taxes due to statutory variation in Excise duty/taxes shall be borne by the supplier. In case of decrease in Excise duty/taxes due to statutory variation in Excise duty/taxes, the same shall be passed on by the supplier to the BPPI.

(b) In case of successful bidder enjoying excise duty exemption on any criteria of turnover, area based etc., such bidder will not be allowed to claim excise duty at a later point of time, during the tenure of contract, when the excise duty is chargeable on goods manufactured.

16.7. Form 'C' shall be provided by BPPI, wherever required. The tenderers should quote the concessional rate of CST applicable in their bids.

17. HANDLING & TESTING CHARGES:

In all supplies, 1.5% of the supply value shall be deducted towards handling & testing charges.

18. LIQUIDATED DAMAGES AND OTHER PENALTIES:

18.1. If the supply reaches the designated places or Central Warehouse after 5 PM of 60th day from the date of issue of the 1st purchase order and after 5 PM of the 45th day from the date of issue of the subsequent purchase order, a liquidated damages will be levied at 2% per week or part thereof, subject to maximum of 10% irrespective of the fact that whether the BPPI has suffered any damage/loss or not, on account of delay in effecting supply. If the 60th/45th day happens to be a holiday the supply will be accepted on the next working day without any penalty.

18.2. If the supply is received in damaged condition, open delivery of the supplies shall be received, wherein it is possible to physically inspect the shipment. Damaged products shall not be accepted.

18.3. All the Tenderers are required to supply the product(s) with printed logogram of appropriate size on the strips, blisters, vials, ampoules & bottles and with prescribed packing specification. If there are any deviation in these Tender conditions, action will be taken to blacklist the product and/or a separate damages will be levied @ 5% of value of the defaulted quantity irrespective of the Tender Inviting Authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause No.14.11 and 13.4.

19. DEDUCTION & OTHER PENALTIES ON ACCOUNT OF QUALITY FAILURE:

19.1. If the samples do not conform to statutory standards, the Tenderer will be liable for relevant action under the existing laws and the entire stock in such batch has to be taken back by the Tenderer within a period of 30 days of the receipt of the letter from the BPPI. Such stock shall be taken back at the expense of the Tenderer. The BPPI has the right to destroy such “NOT OF STANDARD QUALITY DRUGS” if the Tenderer does not take back the goods within the stipulated time. The BPPI will arrange to destroy the “NOT OF STANDARD QUALITY DRUGS” after the expiry of 30 days mentioned above without further notice, and shall also collect demurrage charges calculated at the rate of 2% per week on the value of the drugs rejected till such time stipulated.

19.2. If any items of Drugs/Medicines supplied by the Tenderer have been partially or wholly used or consumed after supply and are subsequently found to be in bad odour, unsound, inferior in quality or description or otherwise faulty or unfit for consumption, then the contract price or prices of total such batches supplied will be recovered from the Tenderer, if payment had already been made to him. In other words the Tenderer will not be entitled to any payment whatsoever for Items of drugs found to be of “NOT OF STANDARD QUALITY” whether consumed or not consumed and the Tender Inviting Authority is entitled to deduct the cost of such batch of drugs from any amount payable to the Tenderer. On the basis of the nature of failure, action will be initiated to blacklist the product/supplier.

19.3. For the supply of Adulterated/Spurious/Misbranded drugs, as defined in the Drugs and Cosmetics Act, 1940, to BPPI, BPPI reserves the right to blacklist the supplier. No further supplies shall be accepted from the firm/company. If the tenderer is blacklisted, the tenderer shall also not be eligible to participate in tenders of Tender Inviting Authority of BPPI for supply of Drugs and Medicines for a period of 5 years from the date of blacklisting. In case of supply of NOT OF STANDARD QUALITY drug(s) to BPPI, the product shall be blacklisted by BPPI and no further supplies shall be accepted for the particular drug(s). The Tenderer shall also not be eligible to participate in tenders of BPPI for supply of such Drugs and Medicines for a period of 2 years from the date of blacklisting. In addition, the Director of Drugs Control of concerned State will be informed for initiating necessary action on the Tenderer in their state. Security deposit will also be forfeited without any intimation.

19.4. The Tenderer shall furnish the source of procurement of raw material utilized in the formulations, if required by the BPPI. The BPPI reserves the right to cancel the purchase orders, if the source of supply is not furnished.

19.5. The decision of the BPPI or any officer authorized by him, as to the quality of the supplied drugs, medicines etc., shall be final and binding. In such cases, the BPPI will be at liberty to terminate the contract either wholly or in part on 30 days notice. The Tenderer will not be entitled for any compensation whatsoever in respect of such termination besides forfeiture of Security deposit.

19.6. For contravention of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the BPPI, and the Tenderer shall be liable to pay for all losses sustained by the BPPI in consequence of the termination which may be recovered from the Tenderer, as per rules besides forfeiture of Security deposit.

19.7. Non performance of any of the contract conditions and provisions will disqualify a firm from participating in the tender for the next 2 years besides forfeiture of Security deposit.

19.8. In the event of making Alternative Purchase, as specified in Clause 12.4 (a), Clause 14.11 and in Clause 15.3 penalty will be imposed on the supplier. The excess expenditure over and above contracted prices incurred by the BPPI in making such purchases from any other sources or in the open market or from any other Tenderer who has quoted higher rates and other losses sustained in the process, shall be recovered from the Security Deposit or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier as per rules.

19.9. In all the above conditions, the decision of the BPPI shall be final and binding.

20. BLACK LISTING IN THE EVENT OF WITHDRAWAL FROM THE TENDER, AND NON-ADHERENCE TO THE QUALITY STANDARDS AND SUPPLY SCHEDULE

20.1. BLACKLISTING OF PRODUCT/TENDERER ON WITHDRAWAL OF TENDER

(a) If the Tenderer(s) fails to execute the agreement / to perform the obligations under the tender conditions / commits default in the performance of the contract, such Tenderers will be blacklisted for a period of 2 years by BPPI from the date of observing the defect besides forfeiture of Security deposit.

BLACKLISTING FOR QUALITY FAILURE

20.2.1. Quality Test by the Empanelled Laboratories of BPPI

a. Each and every batch of drugs/medicines shall be subjected to quality test by the Empanelled laboratories.

b. The samples collected from each batch of supply of the each drugs will be sent to the empanelled testing laboratories for testing the quality of drugs. In addition to the above BPPI shall also draw the samples of products supplied in the market place and get the same tested, to make sure the products are conforming to quality requirements.

c. If such sample passes quality test in all respects, BPPI will instruct its Warehouse to release such items of drugs.

d. If the sample fails in quality test and report is received certifying that sample is “NOT OF STANDARD QUALITY”, one more sample shall be drawn from the same batch and to be sent to Government Laboratory for quality testing.

(i) If such sample passes the quality test as per the report of Government Laboratory, the drugs representing the sample shall be qualified for issue to various Institutions.

(ii) If such sample fails in the quality test, as per the report of the Government Laboratory, the drugs of the batch are not qualified for issue and the supplier shall take back the drugs supplied in that batch, besides taking other actions as per the Tender conditions by BPPI.

(iii) If such Sample fails in quality test for ASSAY content of less than 50% as per the Government Analyst report, such product of the tenderer will be blacklisted for two years.

(iv) If 3 batches of a particular item supplied by the supplier is reported to be failing in ASSAY content (above 50% but below prescribed limit) and/or other parameters, then the particular item of the firm shall be blacklisted after observing procedure laid down in Para 20.2.4 besides forfeiture of Security Deposit of that particular product(s).

f. In all the cases the reports received from the Government Drug Testing Laboratory will be conclusive and final and binding on the suppliers.

20.2.2 Quality Test by Statutory Authorities:

(a) On complaint from Drug Inspector(s) during their Test of statutory sample, that the particular drug has been reported to be of “NOT OF STANDARD QUALITY”, the issue of available stock of the particular item will be stopped. Further, the available stock of the product in hospitals will be retrieved. If the sample is reported to have less than 50% of content, the particular product will be **blacklisted for 2 years from the date of intimation of blacklisting.**

(b) If 4 batches of a particular item supplied by the supplier is reported to be failing in **ASSAY content (above 50% but below prescribed limit) and/or other parameters.** then the particular item of the firm shall be blacklisted for a period of **2 years** from the date of intimation after observing procedure laid down in Para 20.2.4.

(c) If a single batch of any product(s) supplied by the company/firm declared as Adulterated/spurious/ Misbranded, as defined in the Drugs and Cosmetics Act, 1940, by the

Government Authorities during the relevant tender period, the company/firm shall be blacklisted for a period of **5 years from the date of blacklisting** after observing procedure laid down in Para 20.2.4.

20.2.3 BLACKLISTING OF THE SUPPLIER FOR QUALITY FAILURE:

a. In case of any sample declared as Adulterated/spurious/ Misbranded, as defined in the Drugs and Cosmetics Act, 1940, by the Government Authorities during, the company/firm shall be blacklisted for a period of **5 years** from the date of intimation besides forfeiture of security deposit in full after observing the procedure laid down in Para 20.2.4.

20.2.4 Procedure for Blacklisting:

(i) On receipt of complaint from Distributer/retailers/customers or report from Govt. Analyst/Drug Testing Laboratory indicating that a particular Item/Drug is “**NOT OF STANDARD QUALITY/ ADULTERATED/ SPURIOUS/ MIS-BRANDED**” (As the case may be), a show cause notice shall be issued to the supplier calling for explanation within 7 days from the date of notice. On receipt of explanation from the supplier, the CEO, BPPI may take appropriate action on merits of the case and impose penalty including the blacklisting of the particular item of the product/company or firm as deemed fit besides forfeiture of Security deposit

(ii) If a particular item of the drug has been blacklisted according to the procedure stated above, the supplier is not eligible to participate in any of the tenders for that particular item floated by the BPPI until the period of blacklisting is over.

(iii) If a supplier company/firm is blacklisted according to the procedure stated above, such supplier is not eligible to participate in any of the tenders floated by the BPPI until the period of blacklisting is over.

20.3 BLACKLISTING FOR NON-SUPPLY:

Notwithstanding various actions and penalties for non-supply and/or delayed supply of the drugs and medicines as stipulated in the terms and conditions of the tender, the BPPI shall take action against the supplier as follows:

(a) If the supplier fails to execute at least 50% of the ordered quantity as mentioned in a single Purchase order and such part supply for **any three Purchase orders of the same drug**, then the product of the supplier will be blacklisted and becomes ineligible to participate in any of the tenders for that particular item(s) by BPPI for a period of **2 years** from the date of intimation for blacklisting besides forfeiture of security deposit of that product(s)

(b) If the supplier supplies more than one item and 50% of such items are blacklisted, the firm is liable to be blacklisted for a period of **2 years from the date of intimation** besides forfeiture of security deposit in full

20.4. Purchase orders, if any, already issued before taking any blacklisting action or orders given in past will not be affected in view of action taken as per above guidelines but all strict quality checks shall be observed for each supply of products.

20.5. The blacklisting of particular product or company/firm will be done without prejudice to other penalties which may be imposed as per the conditions of Tender documents and also to other actions which may be initiated under Drugs and Cosmetics Act 1940 or any other law of Land. BPPI will display names of such blacklisted product(s) and company/firm on its website and also circulate the same among other state Government / Central Government and its Drug procurement agencies including respective State Drugs Control Department where the company or firm is located.

21. SAVING CLAUSE

No suit, prosecution or any legal proceedings shall lie against the Tender Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of the tender.

22. RESOLUTION OF DISPUTES

(i) The BPPI and the supplier shall make every effort to resolve, amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the contract,

ARBITRATION AND JURISDICTION

Normally, there should not be any scope of dispute between the BPPI and the supplier after entering into a mutually agreed valid contract/agreement.

However, due to various unforeseen reasons, problems may arise during the progress of the contract/agreement leading to disagreement BPPI and the supplier shall first try to resolve the same amicably by mutual Consultation. If the parties fail to resolve the dispute by such mutual consultation within twenty-one days, then, depending on the position of the case, either the BPPI or the supplier shall give notice to other party of its intension to commence Arbitration procedure as per Indian Arbitration and Conciliation Act, 1996. Such disputes/differences shall be referred to Sole Arbitrator to be appointed by the President/ CEO of BPPI. The venue of Arbitration Shall be at New Delhi. The award published by the Arbitrator shall be final and binding on the parties.

23. APPEAL:

(i) Any Tenderer aggrieved by the order passed by the Tender Accepting Authority under section 10 of the said Act, may appeal to the Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India within ten days from the date of receipt of order and the Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India shall dispose the appeal within fifteen days from the date of receipt of such appeal.

(ii) No Appeal shall be preferred while the tender is in process and until tender is finalized and Notification of award is issued by the BPPI.

24. CONTACTING THE BPPI BY THE BIDDER:

(i) No bidder shall contact the *BPPI* on any matter relating to its bid, from the time of bid opening to the time the contract is awarded.

(ii) Any effort by a bidder to influence the *BPPI* in the *Purchaser's* bid evaluation, bid comparison or contract award decisions may result in rejection of the bidder's bid.

(ii) The bidder shall not make any attempt to establish unsolicited and unauthorized contact with the Tender Accepting Authority, Tender Inviting Authority or Tender Scrutiny Committee after opening of the bids and prior to the notification of award and any attempt by any bidder to bring to bear extraneous pressures on the Tender Accepting Authority, Inviting Authority or Tender Scrutiny Committee, shall be sufficient reason to disqualify the bidder.

(iv) Notwithstanding anything contained in clause (iii) above the Tender Inviting Authority or the Tender Accepting Authority, may seek bonafide clarifications from bidders relating to the bids submitted by them during the evaluation of bids.

25. FRAUDULENT AND CORRUPT PRACTICES:

(1)For bidders:

It is purchaser's policy to ensure that suppliers and their authorized representatives/agents observe the highest standard of ethics during the procurement and execution of such contracts. *(In this context, any action taken by a bidder, supplier, contractor, or by their*

authorized representatives/agent, to influence the procurement process or contract execution for undue advantage is improper) In pursuance of this policy, the purchaser;

(a) defines, for the purposes of this provision, the terms set forth below as follows:

(i) “corrupt practice” is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party (*“another party” refers to a public official acting in relation to the procurement process or contract execution*). In this context, “public official” includes staff and employees of other organizations taking or reviewing procurement decisions.

(ii) “fraudulent practice” is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation (*a “party” refers to a public official; the terms “benefit” and “obligation” relate to the procurement process or contract execution; and the “act or omission” is intended to influence the procurement process or contract execution*).

(iii) “collusive practice” is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party [*“parties” refers to participants in the procurement process (including public officials) attempting to establish bid prices at artificial, non competitive level*].

(iv) “coercive practice” is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party (*a “party” refers to a participant in the procurement process or contract execution*).

(v) “obstructive practice” is (a) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or acts intended to materially impede the exercise of the purchaser’s inspection and audit rights provided for under sub-clause (e) below.

(b) will reject a proposal for award if it determines that the bidder considered for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for the contract in question;

(c) will cancel the contract if the purchaser determines at any time that the bidder, supplier and contractors and their sub contractors engaged in corrupt, fraudulent, collusive, or coercive practices.

(d) will sanction a firm or individual, including declaring in eligible, either indefinitely or for a stated period of time, to be awarded a contract if it at any time determines that the firm has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for, or in executing, a contract; and

(e) will have the right to inspect the accounts and records of the bidders, supplier, and contractors and their subcontractors/authorized representatives and to have them audited by auditors appointed by the purchaser.

(2) For suppliers:

If the BPPI determines that a Supplier has engaged in corrupt, fraudulent, collusive, coercive or obstructive practices, in competing for or in executing the Contract, then the BPPI may, after giving 7 days notice to the Supplier, terminate the Supplier's engagement under the Contract and cancel the contract, and the procurement will be made at the risk and cost of the supplier besides blacklisting the bidder for 5 years with forfeiture of Security Deposit apart from other penal actions.

(a) For the purposes of this Sub-Clause:

(i) “corrupt practice” is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party;

(ii) “fraudulent practice” is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation;

(iii) “collusive practice” is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party;

(iv) “coercive practice” is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party;

(v) “obstructive practice” is (aa) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a purchaser investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or (bb) acts intended to materially impede the exercise of the purchaser’s inspection and audit rights provided for.

26. JURISDICTION

In the event of any dispute arising out of the tender such dispute would subject to the jurisdiction of the Civil Court within the city of Delhi only.

ANNEXURE -I

Ref. Clause No. 2(e)(i)

DECLARATION

I.....
Managing Director/Partner/Proprietor of M/s.
.....
having its manufacturing or import unit/ registered office at.....do
hereby declare that our company/applied items have not been
blacklisted/debarred/deregistered either by any State government or Central Government
Organization or its drug procurement agencies for the following products quoted in the
tender. We are eligible to participate in the tender ref. No. **BPPI/DRUG/025 Dt. 13-07-2015**
for the following products.

S. No.	Drug Code	Name of the Drug

M/s.....

(Company Seal)

To be attested by the Notary

ANNEXURE II

Reference clause 2(f)

GS1 barcode requirements on surgical items procured by Bureau of Pharma Public Sector undertakings of India (BPPI)



These requirements cover medicines/drugs procured by Bureau of Pharma Public Sector Undertakings of India (BPPI), Gurgaon, meant for supply and distribution through BPPI regulated distribution channel.


Barcode requirements using GS1 identification standards are provided below at various levels of product packaging which include at primary, secondary and shipper/carton levels and need to be complied with while supplying medicines/drugs to BPPI.

Barcodes using GS1 global standards are required to be printed on product packaging at primary, secondary and tertiary packaging levels **in addition** to other, existing statutory labelling & marking requirements.

Technical Specification for GS1 Standards

Tertiary Level Pack: Data attributes captured in case of homogenous pack a) <i>Unique product identification code (GTIN - Global Trade Identification Number)</i> b) <i>Expiry date</i> c) <i>Batch no.</i> d) <i>Serial Shipping Container Code (SSCC)</i> e.g. 1 st Barcode : (01) 5 8901072 00253 4 (17) 180815 (10) RNBXY0514 2 nd Barcode : (00) 1 8901072 001234567 6				
Attribute	Description	Length	Nature	Data Type
(01)	<i>Application Identifier to indicate GTIN-14 Brackets not encoded in the barcode</i>	2	<i>Fixed</i>	<i>Numeric</i>
5 8901072 00253 4	<i>Unique Product Number-GTIN-14</i>	14	<i>Fixed</i>	<i>Numeric</i>
(17)	<i>Application Identifier to indicate Expiry date Brackets not encoded in the barcode</i>	2	<i>Fixed</i>	<i>Numeric</i>
180815	<i>Expiry Date YY/MM/DD</i>	6	<i>Fixed</i>	<i>Date</i>
(10)	<i>Application identifier to indicate Lot/batch number</i>	2	<i>Fixed</i>	<i>Numeric</i>

	<i>Brackets not encoded in the barcode</i>			
<i>RNBXY0514</i>	<i>Batch No / Lot No</i>	<i>20</i>	<i>Variable</i>	<i>Alphanumeric</i>
<i>(00)</i>	<i>Application identifier to indicate the SSCC Brackets not encoded in the barcode</i>	<i>2</i>	<i>Fixed</i>	<i>Numeric</i>
<i>1 8901072 001234567 6</i>	<i>Unique number of the tertiary pack</i>	<i>18</i>	<i>Fixed</i>	<i>Numeric</i>
<i>Recommended Barcode Symbology – GS-128</i>	<div><div><div>To, ABC Biosciences Company 6480 Dobbin Road Columbia, MD 21045</div><div>Manuf By: AAA Pharma Company Plot No 125, Special Pharma Zone Village Matoda District: Ahmedabad-382213 Gujrat, India</div></div><div><div><p>(01) 5 8901072 00253 4 (17) 180815 (10) RNBXY0514</p><p>(00) 1 8901072 001234567 6</p><div>Drug Name: DOBUCIN 5X5 ML INJ Expiry Date: Aug 15, 2018 Batch No: RNBXY0514</div></div></div></div>			
	Tertiary Level Pack: Data attributes captured in case of heterogeneous pack a) <i>Serial Shipping Container Code (SSCC)</i> e.g. <i>Barcode : (00) 1 8901072 001234567 6</i>			
Attribute	Description	Length	Nature	Data Type
<i>(00)</i>	<i>Application identifier to indicate the SSCC Brackets not encoded in the barcode</i>	<i>2</i>	<i>Fixed</i>	<i>Numeric</i>
<i>1 8901072 001234567 6</i>	<i>Unique number of the tertiary pack</i>	<i>18</i>	<i>Fixed</i>	<i>Numeric</i>
<i>Recommended Barcode Symbology – GS-128</i>				



	<p>To,</p> <p>ABC Biosciences Company 6480 Dobbin Road Columbia, MD 21045</p>	<p>Manuf By: AAA Pharma Company Plot No 125, Special Pharma Zone Village Matoda District: Ahmedabad-382213 Gujrat, India</p>
	<p>Drug Name: DOBUCIN 5X5 ML INJ</p>  <p>(00) 1 8901072 001234567 6</p>	

Secondary Level Pack: Data Attributes Captured

- Unique product identification code (GTIN)
- Expiry date
- Batch No.
- Unique Serial No. of the Secondary pack {Serialization}

e.g. (01) 1 8901072 00253 6 (17) 180815 (10) RNBXY0514 (21) 15892152002

Attribute	Description	Length	Nature	Data Type
(01)	Application Identifier to indicate GTIN-14. Brackets not encoded in the barcode	2	Fixed	Numeric
1 8901072 00253 6	GTIN-14- Unique product code with first digit being the packaging indicator	14	Fixed	Numeric
(17)	Application Identifier to indicate Expiry date Brackets not encoded in the barcode	2	Fixed	Numeric
180815	Expiry Date YY/MM/DD	6	Fixed	Date
(10)	Application identifier to indicate Lot/batch Brackets not encoded in the barcode	2	Fixed	Numeric
RNBXY0514	Batch No / Lot No	20	Variable	Alphanumeric

(21)	<i>Application Identifier to indicate serial number</i> <i>Brackets not encoded in the barcode</i>	20	Variable	Alphanumeric
15892152002	Serial Number	20	Variable	Alphanumeric
<p><i>Recommended Barcode Symbology – GS1 Datamatrix or GS1-128</i></p> <div style="text-align: center;">  (01) 1 8901072 00253 6 (17) 180815 (10) RNBXY0514 (21) 15892152002 or  (01) 1 8901072 00253 6 (17) 180815 (10) RNBXY0514 (21) 15892152002 </div>				

Primary Level Pack: GTIN and Serial Number e.g.(01) 0 8901072 00253 9 (21) 1256897542				
Attribute	Description	Length	Nature	Data Type
(01)	<i>Application Identifier to indicate GTIN-14</i> <i>Brackets not encoded in the barcode</i>	2	Fixed	Numeric
0 8901072 00253 9	<i>GTIN-14 with first digit being the packaging indicator</i>	14	Fixed	Numeric
<i>Additional Info in case of mono carton-</i>				
8901072002539	GTIN-13	13	Fixed	Numeric

<p><i>Recommended Barcode Symbology – GS1 Datamatrix, In case of monocarton additional 1D code would be recommended</i></p>	<div data-bbox="893 246 1069 425" data-label="Image"></div> <div data-bbox="898 425 1064 477" data-label="Text"> <p>(01) 0 8901072 00253 9 (21) 1256897542</p> </div> <div data-bbox="707 504 1257 542" data-label="Text"> <p>(01) 0 8901072 00253 9 (21) 1256897542</p> </div> <div data-bbox="863 564 1099 600" data-label="Section-Header"> <p>GS1 Data matrix</p> </div> <div data-bbox="539 624 1423 701" data-label="Text"> <p><i>In case of mono-carton additional 1D code in form of GTIN-13 is also recommended –</i></p> </div> <div data-bbox="876 723 1101 887" data-label="Image"></div> <div data-bbox="855 860 1098 887" data-label="Text"> <p>8 901072 002539</p> </div>
---	---

Please contact GS1 India office for any further assistance –

Ankit Arora

GS1 India

(Under Min. of Commerce, Govt. of India)

330, 2nd Floor, ‘C’ Wing, August Kranti Bhawan,

Bhikaji Cama Place, New Delhi - 110066

T +91-11-42890890, (D) +91-11-42890846

M +91-95822-00491

F +91-11-26168730

E ankit@gs1india.org

W <http://www.gs1india.org>

ANNEXURE -III

Ref. Clause No. 4.1(h)

PROFORMA FOR PERFORMANCE STATEMENT

Certified that M/sholding drug license no
.....has manufactured & sold the following products for last 3 years as
per details below:

S.No.	Name of the Product	Year of Manufacturing	No. of batches manufactured/imported & supplied	Batch No. Batch Size
1.				
2.				
3.				
4.				
5.				

State Licensing Authority

Signature and seal of the Tenderer.....

ANNEXURE - IV

Ref. clause No. 4.1 (j)

DECLARATION

I/We M/s. Represented by its Proprietor/Managing Partner
/Managing Director having its registered office atand its
factory premises atand
its factory premises at

.....do declare that I/we have carefully read all the conditions of tender in ref.
no. **BPPI/DRUG/025/2015 Dt. 13/07/2015** public sector under taking of INDIA,
GURGAON, 122016 and accept all conditions of the Tender.

I/We declare that we possess the valid drug manufacturing licence and GMP
Certificate as per schedule M issued by competent authority and complies and continue to
comply with the condition lied in schedule M of Drug & cosmetic act, 1940 the rules made
there under.

I am / We are aware of the Tender inviting Authority's right to forfeit the Earnest
Money Deposit and /or Security Deposit and blacklist me/us for a period of 5 years if, any
information furnished by us proved to be false at time the of inspection and not complying
the condition as per schedule M of the said Act for a period of five years.

Signature :

Name &Address:

Seal:

To be Notarized.

ANNEXURE -V

Ref. Clause No. 4.1(k)

ANNUAL TURNOVER STATEMENT

The annual Turnover of M/s.for the past three years are given below and certified that the statement is true and correct.

Sl.No.	Financial Year	Turnover in Lakhs(Rs.)
1.	2012-13	
2.	2013-14	
3.	2014-15	
TOTAL		Rs.....Lakhs
Average Turnover per annual		Rs.....Lakhs

Date:

Signature of Auditor/Chartered Account

Seal:

(Name in Capital)

ANNEXURE-VI
Ref. Clause No.4.1(m)

Form Or Certificate of Sales Tax Verification (Performa of states as prescribed will also be accepted)

(To be filled up by the applicant)

01.	Name or style in which the applicant is assessable sales tax addresses or assessment.	
02.	a) Name and address of all companies firms or associations or persons in which the applicant is interested in his individual or fiduciary capacity.	
	b) Places of business of the applicant (All places of business should be mentioned)	
03.	The districts, taluks and divisions in which the applicant is assessed to sales tax (all the places of business should be furnished)	

04	a) Total counteract amount or value of patronage received in the preceding three year:					
	S. No.	Financial Year	Turn Over			
	1.	2012-13				
	2.	2013-14				
	3.	2014-15				
	b) Particulars of Sales-Tax for the preceding three years:					
	Year	Total Turn Over be assessed	Total Tax assessed (Rs.)	Total Tax paid (Rs.)	Balance due (Rs.)	Reason for balance (Rs.)
	2012-13					
	2013-14					
	2014-15					
	c) if there has been no assessment in any year, whether returns were submitted any, if there were, the division in which the returns were sent :					
	d) Whether any penal action or proceeding for the recovery of Sales Tax is pending					
	e) The name and address of Branches. If any:					

I declared that above information is correct and complete to the best of my knowledge and belief.

Signature of Applicant: _____

Date: _____

Address: _____

(To be filed by the assessing authority)

In my opinion, the applicant mentioned above has been / has not been / doing everything possible to pay the tax demand promptly and regularly and to facilitate the completion of pending proceedings.

Date seal : Deputy / Asst. Commercial tax – officer
Deputy Asst.

NOTE: Separate certificate should be obtained in respect of each of place of business of the applicant from the deputy commercial tax officer having jurisdiction over that place.

ANNEXURE -VII

Ref. Clause no 4.1 (n) (i)

DECLARATION

I do hereby declare that I will supply the drug and medicines as per the design in enclosures to this Annexure as well as other instruction given in this regard.

Signature of the Tenderer

(Name in capital letter with designation)

Attested by Notary Public

ANNEXURE –VII(A)

Ref. Clause No. 4.1 (n)(ii)

UNDERTAKING

I / we do hereby declared that I will supply the drugs and medicine by affixing logo on Primary/Secondary/ Tertiary packing for the imported items along with the generic name as per the designs given in enclosures to this annexure as well as other instructions given in this regard.

Signature of the Tenderer

(Name in capital letter with designation)

Attested by Notary Public

Enclosure–1 to ANNEXURE -VII AND VII(A) - Refer Clause No .4.1. (n)

DESIGN FOR: Foil / blister of tablet and capsule

1. Foil /Blister should be in minimum two colour i.e. Black & red
2. BPPI Logogram should be placed along with the address as given below
3. BPPI helpline number 1800 180 8080 should be printed

Manufactured for :



Bureau of Pharma Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Or

Manufactured for :



Bureau of PharmaPublic Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

4. Janaushadhi should be printed in “Inverse red colour” in English and Hindi as

Janaushadhi(English) Jan Aushadhi(In Hindi)

Enclosure – 2 to ANNEXURE –VII & ANNEXURE –VII(A)

Ref. Clause No. 4.1.(n) & Clause No. 13

1. Design for injection for primary packing

- a) Vial (5ml or more) should be supplied with the following Jan Aushadhi logogram & BPPI as under:
- b) BPPI helpline number 1800 180 8080 should be printed



Manufactured for :



Bureau of Pharma Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Or

Manufactured for :



Bureau of Pharma Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

b) Ampoules or Vials less than 5 ml for primary packing

- (i) Injection in ampoule or vial (less than 5 ml) should be supplied with BPPI logogram as under (colour should be black)

Manufactured for :



Bureau of Pharma Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Or

Manufactured for :



Bureau of Pharma Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

2. LIQUID:

- a) Liquid preparation should be supplied with pilfer proof ROPP cap.
- b) Bottle cap should not bear the manufacturer's logogram
- c) Bottle label should bear JANAUSHADHI logogram as below:
- d) BPPI helpline number 1800 180 8080 should be printed



Manufactured for :



Bureau of Pharma Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

3. OINTMENTS / CREAMS

- a) Ointment / Cream /Gel /Glass Jar should bear BPPI logo gram as below:

Manufactured for :



Bureau of Pharma Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

- b) BPPI helpline number 1800 180 8080 should be printed
- c) Ointment / cream tube should be packed in mono carton (secondary packing) with janaushadhi and BPPI logogram as given below. **Logo in 4 colors will also be accepted.**



Manufactured for :



Bureau of Pharma Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Enclosure 3 to ANNEXURE –VII(A)

SPECIMEN LABEL FOR MONO CARTON (Secondary Packing)

Rx
Tablets

10 X 10's

Generic Name of Product



Note: An additional to statutory requirement under Drug & Cosmetic Act 1940 and rules 1945

Manufactured for :



Bureau of Pharma Public Sector Undertakings of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

ANNEXURE – VIII

Ref. Clause No.4.1 (0)

DETAILS OF MANUFACTURING /IMPORTING UNIT

Sl.No.	Details	
1.	Name of the Tenderer & Full Address	
2.	PAN Number	
3.	TIN Number	
4.	Phone Nos.	
5.	Fax	
6.	E-Mail ID	
7.	Date of Inception	
8.	Licence No. & Date	
9.	Issued By	
10.	Valid Upto	

Details of Installed Production Capacity for 1 year

(In Terms of Unit Packs)

S.No.	Details	
1.	Tablets	
2.	Capsules	
	a) General	
	b) Beta-Lactum	
3.	Injections	
	a) Ampoules	
	b) Vials	
	c) I.V. Fluids	
	d) Sterile Powder	
4.	Liquids	
	a) Suspension	
	b) Syrups	
	c) Drops	
5.	Ointment	
6.	Powders	
7.	Antiseptics / Disinfectants	
8.	Name & designation of the authorized Signatory	
9.	Specimen signature of the authorized Signatory	

* The details of manufacturing unit shall be for the premises where items quoted are actually manufactured.

ANNEXURE – IX

Ref. clause 4.1 (r)

LIST OF ITEMS QUOTED

Sl.No.	Details																			
1.	Name of the firm and address (As given in Drug licence)																			
2.	Drug Licence No. in form 25 & 28 Or import Licence No.																			
3.	Date of issue & validity																			
4.	GMP certificate obtained on																			
5.	Non-conviction Certificate Obtained on																			
6.	Market standing Certificate Obtained on																			
7.	Details of Endorsement for all products quoted :																			
<table border="1" style="width: 100%; border-collapse: collapse;"><thead><tr><th style="width: 10%;">Sl.No.</th><th style="width: 10%;">Drug Code</th><th style="width: 20%;">Drug Name</th><th style="width: 20%;">Specifications IP/BP/USP</th><th style="width: 20%;">Date of Endorsement obtained from the State Drugs Controller</th><th style="width: 20%;">Whether Endorsement is in Generic or Trade Name</th></tr></thead><tbody><tr><td>1.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2.</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>			Sl.No.	Drug Code	Drug Name	Specifications IP/BP/USP	Date of Endorsement obtained from the State Drugs Controller	Whether Endorsement is in Generic or Trade Name	1.						2.					
Sl.No.	Drug Code	Drug Name	Specifications IP/BP/USP	Date of Endorsement obtained from the State Drugs Controller	Whether Endorsement is in Generic or Trade Name															
1.																				
2.																				
Authorised signatory: Date:																				

ANNEXURE – X

Ref. Clause 4.1 (s)

CHECK-LIST

COVER – A

S.No.	Check List	Page no	YES	NO
1.	Checklist - ANNEXURE – X			
2.	EMD in the form of DD shall be kept in an Envelope as per ANNEXURE-XI SSI certificate For exemption			
3.	Undertaking of in form ANNEXURE -VI			
4.	Documentary evidence for the constitutions of the company / concern			
5.	Duly attested photocopy of License for the Product duly approved by the Licensing Authority for each and every product quoted			
6.	Duly attested photocopy of Import License, if Imported and whole sale Drug license			
7.	The instruments such as power of attorney, Resolution of board etc.,			
8.	Authorization letter nominating a responsible Person of the tenderer to transact the business with the Tender inviting Authority			
9.	Market Standing Certificate issued by the Licensing Authority			
10.	WHO Certificate if any			
11.	Non Conviction Certificate issued by the licensing authority			
12.	Good Manufacturing Practices Certificate			
13.	Latest income tax assessment orders/returns filed.			
14.	Copies of balance sheet & profit loss account for three years			
16.	ANNEXURE-I (Declaration for eligibility in participating the tender)			
17.	ANNEXURE –II (Bar Coding)			
18.	ANNEXURE –III (Proforma for Performance Certificate)			
19.	ANNEXURE –IV (Declaration for acceptance			

	of tender conditions and compliance of GMP)			
20.	ANNEXURE -V (Annual Turnover Statement for three years.) For loan licensee, turnover of host(actual manufacturer) company also needs to be attached.			
21.	ANNEXURE-VI (Sales Tax Clearance Certificate)			
22.	ANNEXURE -VII (Undertaking for embossment of LOGO)			
23	ANNEXURE –VII A(Undertaking for embossment of LOGO)			
23.	ANNEXURE -VIII (Details of Manufacturing Unit)			
24.	ANNEXURE -IX (List of Items quoted without rates) along with soft copy.			
25.	ANNEXURE-XII(Notarised Undertaking)			
26	ANNEXURE—XVII (Mandate form)			
27	The tender document signed by the tenderer on each pages with official deal.			

Cover “B”

S.No.	Check List	YES	NO
1.	ANNEXURE XVIII duly filled		
2.	ANNEXURE XIX duly filled		
3.	Pen drive/compact disc having duly filled ANNEXURES-- XVIII and XIX		

Name and signature of authorised signatory (with company seal)

ANNEXURE -XI

Ref. Clause No. 7.1 & 3(ii)

DETAILS OF E.M.D SUBMITTED

We herewith submit the E.M.D. of Rs.....in the form of Demand
Draft bearing No..... Dated:drawn
on.....BankBranch in favour of
Bureau of Pharma Public sector Undertakings of India.

Signature & Seal

ANNEXURE -XII

Ref. Clause No. 7.2

NOTORISED UNDERTAKING

(In 20-Rupees Stamp Paper)

I.....,S/o.....,Proprietor/Partner/
Managing Director of(Proprietary Concern/Firm/Company Ltd.)
execute this undertaking for myself and on behalf
of.....(Proprietary Concern/Firm/Company Ltd.).

And whereas, in pursuant to the conditions in Clause No. 7.2 of the tender, the Earnest Money Deposit can be forfeited by the Tender Inviting Authority in case of violation of any of the conditions and non-performance of the obligation under tender document.

M/s.....

For Self and Firm/Company Ltd.

(Signature and Seal)

Witness:-

(1).....

(2).....

ANNEXURE -XIII**(Ref Clause 8.1 & 8.2)****BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)****TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015**

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
1	14	Ibuprofen 400 mg+ Paracetamol 325 mg Tabs.	10's	10'sx10	10'sx10x10	200000
2	15	Ibuprofen 200 mg Tabs.	10's	10'sx10	10'sx10x10	500000
3	16	Ibuprofen 400 mg Tabs.	10's	10'sx10	10'sx10x10	100000
4	25	Serratiopeptidase Tablets 10 mg	10's	10'sx10	10'sx10x10	105000
5	53	Cefixime Oral Suspension IP 50 mg/5 ml	30 ml bottle	1'Sx10	1'Sx10x20	200000
6	60	CEFOTAXIME SODIUM 250 MG & SULBACTAM SODIUM 125 MG INJECTION	VIAL & WFI	1'sx10	1'sX10X20	75000
7	83	CIPROFLOXACIN 250 MG+ TINIDAZOLE 300 MG FILM COATED TABLETS	10's	10'sx10	10'sx10x10	96000
8	89	CO-TRIMOXAZOLE TABLETS IP (160 MG + 800 MG)	10's	10'sx10	10'sx10x10	120000
9	112	BECLOMETHASONE IP 0.025% w/w+ CLOTRIMAZOLE IP 1% w/w+ GENTAMYCIN IP 0.1% w/w CREAM	15 GM	15 GMX20	15 gm x 20x 20	2,70,000
10	115	Calamine lotion 100 ml	100ml bottal		100x100ml	100000
11	127	Povidone Iodine 5% Solution 100ml	100ml bottal		100x100ml	100000
12	143	BIPHASIC INSULIN ASPART INJECTION IP 100 IU/ML (30:70)	VIAL	VIALX10	VIALX10X20	47000
13	144	METFORMIN HYDROCHLORIDE SUSTAIN RELEASE TABLETS IP 1000 MG	10's	10'sx10	10'sx10x10	200000
14	153	CISPLATIN INJECTION IP 10 MG	VIAL & WFI	1'Sx20	1 X 20 X 50	100000
15	165	CIPROFLOXACIN INJECTION IP 2MG/ML	100 ML	100 ML x 10	100 ML x 10X10	100000
16	191	FAMOTIDINE TABLETS IP 20 MG	14's	14'sx10	14'sx10x10	485000
17	192	FAMOTIDINE TABLETS IP 40 MG	14's	14'sx10	14'sx10x10	1010000
18	194	Hyoscine Butyl Bromide film coated tablet 10 mg	10's	10'sx10	10'sx10x10	200000
19	196	LACTOBACILLUS SPOROGENES 60 MILLION SPORES TABLETS	10's	10'sx10	10'sx10x10	243000
20	201	METRONIDAZOLE 200 MG FILM COATED TABLETS	10'S	10'sx10	10'sx10x10	200000
21	202	METRONIDAZOLE 400 MG FILM COATED TABLETS	10'S	10'sx10	10'sx10x10	500000
22	208	ONDENSETRON INJECTION IP 2 mg/ml	2 ML	2 ml x 10	2 ml x 10 x 50	120000
23	213	Pantoprazole 40mg/10ml Inj.	vial		20x10x10	200000
24	216	RANITIDINE INJECTION IP 50 MG/ 2ML	2 ML	2 ml x 10	2 ml x 10 x 50	760000
25	225	IRON HYDROXIDE POLYMALTOSE COMPLEX EQ TO ELEMENTAL IRON 50 MG+ FOLIC ACID 0.5 MG /5 ML SYRUP	200 ML	1's	200 ML X 20	100000
26	229	Haematinic Syrup of Iron , acid and Vitamin B12 100ml	100ml bottal		100x100ml	100000
27	230	VITAMIN B COMPLEX (B1,B2,B6,B12) & VIT. C WITH ZINC 22.5 MG CAPSULES	10's	10'sx10	10'sx10x10	517000

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
28	231	VITAMIN B1 10MG, B2 10 MG, NIACINAMIDE 45 MG, CALCIUM PANTOTHENATE 50 MG, B6 3 MG AND B12 15 MCG TABLETS	10's	10'sx10	10'sx10x10	1924000
29	232	VITAMIN B-VOMPLEX Syrup NFI	200 ML	1's	200 ML X 20	200000
30	235	BUDESONIDE RESPULES 0.5 MG	2 ML	2 ml x 10	2 ml x 10 x 50	912000
31	241	COUGH SYRUP DEXTROMETHORPHAN HBR10 mg+ CPM 4 MG /10 ML SYRUP	100 ML	100 ML x 10	100 ML x 10X10	185000
32	244	THEOPHYLLINE 25.3 MG+ ETOPHYLLINE 84.6MG INJECTION 2 ML	2 ML	2 ml x 10	2 ml x 10 x 50	1746000
33	255	SALBUTAMOL INHALATION IP 100 µg/ METERED DOSE	200 MD	200 MD	200 MD X100	182000
34	256	salbutamol 2mg tablets	10x10		100x10x10	200000
35	278	FRUSEMIDE INJECTION IP (10 MG/ ML)	2 ML	2 ml x 10	2 ml x 10 x 50	107000
36	285	AMLODIPINE 5 MG + LISINOPRIL 5 MG TABLETS	15's	15'sx10	15'sx10x10	103000
37	302	TRANEXAMIC ACID 500 MG/5 ML	5 ML AMPULE	5 ML X 10	5 MLX10X50	210000
38	306	PRIMAQUINE TABLETS IP 15 MG	7's	7's X 10	7'sx10x10	120000
39	323	FLUNARZINE TABLETS 10MG	10's	10'sx10	10'sx10x10	200000
40	324	FLUNARZINE TABLETS 5MG	10's	10'sx10	10'sx10x10	95000
41	329	PREDNISOLONE TABLETS IP 5 MG	15's	15'sx10	15'sx10x10	1573000
42	331	THYROXINE SODIUM TABLETS IP 50 µg	10's	10'sx10	10'sx10x10	210000
43	333	dexamethazole 0.5 mg Tablets	10x10		100x10x10	200000
44	334	DEXAMETHASONE INJECTION IP 4 MG/ML	2 ML	2 ml x 10	2 ml x 10 x 50	1112000
45	338	ATROPINE SULPHATE INJECTION IP 0.6MG/ ML	1 ML	1 MLX10	1 ML X10X100	100000
46	341	CARBOXY METHYL CELLULOSE EYE DROPS IP 0.5% w/v	10 ML	10 MLX10	10 MLX10X20	100000
47	344	Ciprofloxacin 0.3% w/V Eye drops	5ml		30x10x5 ml	500000
48	345	gentamycin 0.3 % w/V eye drops	5ml		30x10x5 ml	500000
49	356	LIGNOCAINE INJECTION IP 2% w/v	20 ML VIAL	20 ML X 10	20 ml x 10 x 10	200000
50	357	Ligncaine 1% + adrenaline 2% W/V inj.	30 ml vial		10x10x30ml	100000
51	358	Propafol 10mg/ ml Inj	10ml vial		20x10x10	100000
52	359	TETANUS VACCINE (Adsorbed) IP	AMP 0.5 ML	1X10	1x10 x100	1160000
53	361	OXYTOCIN INJECTION IP 5 UNITS/ML	1 ML	1 ML X 10	1 MLX10X100	1000000
54	362	BIPHASIC ISOPHANE INSULIN INJECTION IP 40 IU/ML (50:50)	10 ML VIAL	10 MLX10	10 MLX10X20	340000
55	366	GLIPIZIDE 5 MG + METFORMIN HYDROCHLORIDE 500 MG TABLETS	10's	10'sx10	10'sx10x10	1309000
56	368	GLICLAZIDE TABLETS SR 60 MG	10's	10'sx10	10'sx10x10	55000
57	369	ACARBOSE TABLETS IP 50 MG	10's	10'sx10	10'sx10x10	46000
58	370	NEUTRAL PROTAMINATED HAGEDORN INJECTION 40 IU	10 ML VIAL	10 MLX10	10 MLX10X20	40000
59	372	METFORMIN HYDROCHLORIDE TABLETS IP PROLONG RELEASE 500 MG	10's	10'sx10	10'sx10x10	100000
60	373	ARTESUNATE INJECTION 60 MG	1 ML	1 MLX10	1	99000

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
					MLX10X100	
61	374	ARTEMETHER 80 MG + LUMEFANTRINE 480 MG SR TABLETS	6's	6's X 10	6's X 10 X 10	91000
62	375	QUININE TABLETS IP 300 MG FILM COATED TABLETS	10's	10'sx10	10'sx10x10	44000
63	377	CLINDAMYCIN CAPSULES IP 300 MG	10's	10'sx10	10'sx10x10	22000
64	378	EACH KIT CONTAIN RIFAMPICIN TABLET IP 450MG, ISONIAZIDE TABLET IP 300MG ETHAMBUTOL TABLET IP 800MG AND PYRAZINAMIDE TABLETS IP 750MG	1's	1'sx10	1X10X100	655000
65	379	RIFAMPICIN and ISONIAZIDE TABLETS IP (450 MG+300 MG)	10's	10'sx10	10'sx10x10	144000
66	382	LINEZOLID TABLETS IP 600 MG	10's	10'sx10	10'sx10x10	95000
67	387	TERBINAFINE 250 MG TABLETS	7's	7'sx10	7'sx10x10	206000
68	388	EACH KIT CONTAIN RIFAMPICIN TABLET IP 450MG, ISONIAZIDE TABLET IP 300MG and ETHAMBUTOL TABLET IP 800MG	1's	1'sx10	1X10X100	484000
69	389	PENICILLIN G 400000 IU TABLETS	6's	6'sX10	6's X 10 X 10	684000
70	390	ETHAMBUTOL TABLETS IP 800 MG	10's	10'sx10	10'sx10x10	129000
71	391	MOXIFLOXACIN TABLETS 400 MG	5's	5'sx10	5'sx10x100	134000
72	392	GRISEOFULVIN TABLETS IP 250 MG	10's	10'sx10	10'sx10x10	220000
73	393	ACICLOVIR DISPERSIBLE TABLETS IP 800 MG	5's	5'sx10	5'sx10x100	47000
74	394	PYRANTEL PAMOATE ORAL SUSPENSION IP 250 MG/10 ML	10 ML	10 MLX10	10 MLX10X20	237000
75	396	AMPHOTERICIN B INJECTION IP. 50MG/ML	20 ML	20MLX10	20MLX10X10	4000
76	397	OXYTETRACYCLINE CAPSULES IP 250 MG	8's	8'Sx10	8'Sx10x10	486000
77	398	RIFAMPICIN TABLETS IP 450 MG	10's	10'sx10	10'sx10x10	28000
78	399	RIFAMPICIN, ISONIAZIDE and PYRAZINAMIDE TABLETS IP (120MG+50MG+300MG)	10's	10'sx10	10'sx10x10	76000
79	403	CLINDAMYCIN INJ IP 300 MG/2 ML	2 ML	2 ml x 10	2 ml x 10 x 50	38000
80	404	LINEZOLID INFUSION 600 MG/300 ML	300 ML	1's	300 ML X 20	577000
81	406	ACICLOVIR INTRAVENOUS INFUSION IP 500 MG/VIAL	VIAL	10'S	10'SX20	98000
82	407	IVERMECTIN TABLETS 12 MG	10's	10'sx10	10'sx10x10	120000
83	408	BENZYL PENICILLIN INJECTION IP 0.6 MILLION UNITS	VIAL	10'S	10'SX20	120000
84	409	BENZYL PENICILLIN INJECTION IP 1.2 MILLION UNITS	VIAL	10'S	10'SX20	120000
85	410	TRASTUZUMAB INJECTION 440 MG with WFI	1's	1'sX10	1X10X10	1000
86	411	BEVACIZUMAB INJECTION 25 MG	1's	1'sX10	1X10X10	1000

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
87	412	AZATHIOPRINE TABLETS IP 50 MG	10's	10'sx10	10'sx10x10	57000
88	413	METHOTREXATE TABLETS IP 7.5 MG	10's	10'sx10	10'sx10x10	35000
89	415	GLYCERYL TRINITRATE TABLETS IP 250 µg	25's	25'sx10	25'sx10x20	194000
90	416	PRAZOSIN TABLETS IP 5 MG	15's	15'sx10	15'sx10x10	137000
91	419	HEPARIN SODIUM 50 IU/20 GM OINTMENT	20 GM	20 GMx20	20 GMx20X10	139000
92	420	ATORVASTATIN 10 MG+ CLOPIDOGREL 75 MG CAPSULES	10's	10'sx10	10'sx10x10	100000
93	421	NEBIVOLOL TABLETS IP 5 MG	10's	10'sx10	10'sx10x10	234000
94	423	BISOPROLOL TABLETS 5 MG	10's	10'sx10	10'sx10x10	121000
95	424	CARVEDILOL TABLETS IP 3.125 MG	10's	10'sx10	10'sx10x10	258000
96	425	DILTIAZEM TABLETS SR 90 MG	10's	10'sx10	10'sx10x10	100000
97	426	ACENOCOUMAROL TABLETS 2 MG	30's	30'Sx10	30'Sx10x10	26000
98	427	S-AMLODIPINE TABLETS IP 2.5 MG	10's	10'sx10	10'sx10x10	366000
99	431	RAMIPRIL and HYDROCLORTHIAZIDE TABLETS IP (5MG+12.5 MG)	10's	10'sx10	10'sx10x10	60000
100	433	ISOSORBIDE MONONITRATE TABLETS IP 30 MG	30's	30'Sx10	30'Sx10x10	42000
101	438	INDAPAMIDE TABLETS IP 1.5 MG	10's	10'sx10	10'sx10x10	50000
102	440	METOPROLOL 50 MG + AMLODIPINE 5 MG TABLETS	7's	7'sx10	7'sx10x10	400000
103	441	LOSARTAN 50 MG+ AMLODIPINE 5 MG TABLETS	10's	10'sx10	10'sx10x10	278000
104	442	FENOFIBRATE CAPSULES IP 150 MG	10's	10'sx10	10'sx10x10	42000
105	443	ISOSORBIDE DINITRATE TABLETS IP 5 MG	50's	50'sx10	50'sx10X50	122000
106	444	ENALAPRIL 10 MG + HYDROCLORTHIAZIDE 25 MG TABLETS	30's	30'Sx10	30'Sx10x10	24000
107	446	AMLODIPINE 5 MG + HYDROCHLOROTHIAZIDE 12.5 MG TABLETS	10's	10'sx10	10'sx10x10	173000
108	447	MOXONIDINE TABLETS 0.3 MG	10's	10'sx10	10'sx10x10	55000
109	448	AMLODIPINE 5 MG+ RAMIPRIL 5 MG TABLETS	10's	10'sx10	10'sx10x10	50000
110	449	SPIRONOLACTONE TABLETS IP 25 MG	15's	15'sx10	15'sx10x10	67000
111	450	LABETALOL TABLETS IP 100 MG	10's	10'sx10	10'sx10x10	25000
112	452	WARFARIN TABLETS IP 5 MG	10's	10'sx10	10'sx10x10	76000
113	453	BISOPROLOL 5 MG+ HYDROCHLOROTHIAZIDE 6.25 MG TABLETS	10's	10'sx10	10'sx10x10	22000
114	454	VALSARTAN TABLETS IP 80 MG	10's	10'sx10	10'sx10x10	30000
115	455	VERAPAMIL TABLETS IP 80 MG	10's	10'sx10	10'sx10x10	120000
116	457	TORASEMIDE TABLETS 20 MG	10's	10'sx10	10'sx10x10	210000
117	461	BETAMETHASONE VALERAT 0.1 % w/w + NEOMYCIN SULFATE 0.5 % w/w CREAM	20 GM	20 GMx20	20 GMx20X10	1513000
118	462	BETAMETHASONE VALERATE and CLIOQUINOL CREAM BP	30 GM	30 GMX10	30 GMX10X10	701000

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
		(0.12w/w+3% w/w)				
119	464	DICYCLOMINE 10 MG + PARACETAMOL 325 MG + TRAMADOL 50 MG CAPSULES	10's	10'sx10	10'sx10x10	1287000
120	468	BACILLUS CLAUSII SPORES ORAL SUSPENSION 2 Billion/ 5 ML	5 ML	5 MLX 10	5MLX10X50	425000
121	469	HEPATIC PROTECTORS SYRUP	200 ML	1's	200 ML X 20	640000
122	470	PEPSIN 10 MG+ DIASTASE 50 MG ORAL LIQUID /5 ML	200 ML	1's	200 ML X 20	234000
123	471	OXETACAINE 10 MG+ ALUMINIUM 291 MG + MAGNESIUM 98 MG /5 ML GEL	200 ML	1's	200 ML X 20	211000
124	472	DOMPERIDONE 30 MG+ ESOMEPRAZOLE 40 MG CAPSULE	10's	10'sx10	10'sx10x10	133000
125	473	LEVOSULPIRIDE 75 MG+ PANTOPRAZOLE 40 MG CAPSULE	10's	10'sx10	10'sx10x10	56000
126	476	LIQUID PARAFFIN 1.25 ML+ MILK OF MAGNESIA 3.75ML+ SODIUM PICOSULPHATE 3.33MG /5ML EMULSION	200 ML	1's	200 ML X 20	137000
127	477	CLIDINIUM 2.5 MG+ CHLORDIAZEPOXIDE 5 MG FILM COATED TABLETS	15's	15'sx10	15'sx10x10	191000
128	479	TRICHOLINE CITRATE 550 MG + SORBITOL 7.15 MG SYRUP/5 ML	200 ML	1's	200 ML X 20	77000
129	480	LEVOSULPIRIDE 75 MG+ ESOMEPRAZOLE 40 MG CAPSULES	10's	10'sx10	10'sx10x10	69000
130	481	RIFAXIMIN TABLETS BP 40 MG	10's	10'sx10	10'sx10x10	48000
131	486	PANCREATIN 170 MG+ DIMETHICONE 80 MG TABLETS	10's	10'sx10	10'sx10x10	200000
132	487	DICYCLOMINE 10 MG + DIMETHICONE 40 MG /5 ML SUSPENSION	30 ML	30 MLX10	30 MLX10X20	172000
133	488	LANSOPRAZOLE CAPSULES IP 15 MG	10's	10'sx10	10'sx10x10	85000
134	489	SULFASALAZINE TABLETS BP 1000 MG ENTERIC COATED	10's	10'sx10	10'sx10x10	73000
135	490	SIMETHICONE 40 MG DROPS	15 ML	15 MLX20	15 MLX20X20	120000
136	492	SULFASALAZINE TABLETS BP 500 MG ENTERIC COATED	10's	10'sx10	10'sx10x10	73000
137	493	ISPAGHULA HUSK IP 50 GM	50 GM	50 GM	50 GMx50	47000
138	494	ISPAGHULA HUSK IP 100 GM	100 GM	100 GM	100 GMX100	47000
139	495	FERROUS AMMONIUM CITRATE 160 MG + CYANO COBALAMINE 7.5 MCG + FOLIC ACID 0.5 MG/15ML SYRUP	200 ML	1's	200 ML X 20	480000
140	496	DYDROGESTERONE TABLETS IP 10 MG	10's	10'sx10	10'sx10x10	101000
141	498	FERROUS ASCORBATE 100MG WITH FOLIC ACID 1.5MG TABLETS	10's	10'sx10	10'sx10x10	253000
142	500	LEVO-THYROXINE TABLETS IP 100 MCG	100's in A Bottle	100 ML X6	100 MLX6X20	269000

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
143	501	BETAMETHASONE SODIUM PHOSPHATE TABLETS IP 0.5 MG	20's	20'sx10	20'sx10x10	2425000
144	503	METHYLPREDNISOLONE SODIUM SUCCINATE INJECTION 1000 MG PER VIAL	VIAL & WFI	1's X 10	1X10X20	50000
145	504	NANDROLONE DECANOATE INJECTION IP 25MG/ML	2 ML	2 ml x 10	2 ml x 10 x 50	57000
146	505	CARBIMAZOLE TABLETS IP 10 MG	100's in Bottle	100 ML X6	100 MLX6X20	19000
147	506	LEVO-THYROXINE TABLETS IP 50 MCG	100's in Bottle	100 ML X6	100 MLX6X20	269000
148	507	CARBIMAZOLE TABLETS IP 5 MG	10's	10'sx10	10'sx10x10	120000
149	514	CHYMOTRYPSIN + TRYPSIN (1:6)ENTERIC COATED TABLETS 100K AU	20's	20'sX10	20'sx10x10	65000
150	519	KETOROLAC TABLETS DT 10 MG	10's	10'sx10	10'sx10x10	167000
151	520	MEFENAMIC ACID 500 MG+ PARACETAMOL 325 MG TABLETS	10's	10'sx10	10'sx10x10	140000
152	521	TRAMADOL TABLETS SR 100 MG	10's	10'sx10	10'sx10x10	50000
153	522	ALFACALCIDOL SOFT GELATIN CAPSULES 0.25 MCG	10's	10'sx10	10'sx10x10	100000
154	523	NAPROXEN TABLETS IP 500 MG	15's	15'sx10	15'sx10x10	49000
155	524	LIDOCAINE INJECTION IP 2 %W/V	30 ML VIAL	30 MLX10	30 MLX10X20	96000
156	526	CHLORPHENIRAMINE 4 MG+ CODEINE 10 MG/5 ML SYRUP	100 ML	100 ML x 10	100 ML x 10X10	1675000
157	527	AMMONIUM CHLORIDE 50 MG+ CHLORPHENIRAMINE MALETAE 2.5 MG+ DEXTROMETHORPHAN 5 MG+ GUAIFENESIN 50 MG / 5ML SYRUP	100 ML	100 ML x 10	100 ML x 10X10	258000
158	529	LEVOSALBUTAMOL 1.25 MCG+ IPRATROPIUM 500 MCG RESPULES/2.5ML	2.5 ML	2.5 ML X10	2.5 MLX10X50	1360000
159	530	FORMOTEROL 6 MG+ BUDESONIDE 200 MG ROTACAP	30's	30'Sx10	30'Sx10x10	89000
160	532	SALMETEROL 50 MG+ FLUTICASONE 250 MG ROTACAP	30's	30'Sx10	30'Sx10x10	47000
161	534	SALBUTAMOL 200 MCG + BECLOMETHASONE 100 MCG ROTACAP	30's	30'Sx10	30'Sx10x10	357000
162	535	TERBUTALINE 2.5 MG + BROMHEXINE 8 MG /10 ML SYRUP	100 ML	100 ML x 10	100 ML x 10X10	192000
163	536	PROMETHAZINE 1.5 MG + PHOLCODINE CITRATE 1.5 MG /5ML LINCTUS	60 ML	60 ML x 10	60 ML x 10 x 10	151000
164	537	SALBUTAMOL 1 MG+ AMBROXOL HYDROCHLORIDE 15 MG/5 ML SYRUP	100 ML	100 ML x 10	100 ML x 10X10	548000
165	538	THEOPHYLLINE TABLETS 400 MG	10's	10'sx10	10'sx10x10	91000
166	540	LEV BUTEROL 1.25 MG+ BUDESONIDE 1MG REPSULE	2 ML	2 ml x 10	2 ml x 10 x 50	209000
167	543	MENTHOL CINNAMON and PINE OIL SOFT CAPSULES	10's	10'sx10	10'sx10x10	128000

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
168	544	FLUTICASONE PROPIONATE RESPULE 0.5 MG/2ML	2 ML	2 ml x 10	2 ml x 10 x 50	117000
169	555	DOXOFYLLINE TABLETS IP 400 MG	10's	10'sx10	10'sx10x10	275000
170	556	MONTELUKAST 10 MG + FEXOFENADINE 120 MG TABLETS	10's	10'sx10	10'sx10x10	147000
171	557	TIOTROPIUM ROTOCAP 18 MCG	15's	15'sx10	15'sx10x10	23000
172	558	FLUTICASONE 50 MCG+ AZELASTINE 140 MCG NASAL SPRAY	120MD	1'sX10	1'sX10X20	13000
173	559	SALBUTAMOL 2MG + THEOPHYLLINE 100 MG TABLETS	30's	30'Sx10	30'Sx10x50	285000
174	560	FLUTICASONE PROPIONATE 50 MCG PER PUFF NASAL SPRAY	120 MD	120 MD	120 MDX100	16000
175	561	LEVOSALBUTAMOL 1 MG/5ML SYRUP	100 ML	100 ML x 10	100 ML x 10X10	137000
176	563	OXYMETAZOLINE 0.5 MG /ML NASAL DROPS	10 ML	10 MLX10	10 MLX10X20	100000
177	564	FORMOTEROL 12 MG + TIOTROPIUM 18 MG ROTOCAP	15's	15'sx10	15'sx10x10	19000
178	565	CICLESONIDE 400 MCG+ FORMOTEROL 12 MCG + TIOTROPIUM 18 MCG ROTOCAP	15's	15'sx10	15'sx10x10	6000
179	566	IPRATROPIUM 250 MCG/ML I:SOLUTION	15 ML	15 ML x20	15 ML x20 X20	26000
180	567	SALBUTAMOL 100 MCG + IPRATROPIUM 20 MCG /PUFF INHALER	100 MD	1's X 10	1'S X10X20	7000
181	568	SALMETEROL 50 MCG+ FLUTICASONE PROPIONATE 250 MCG /PUFF INHALER	100 MD	1's X 10	1'S X10X20	28000
182	571	TAMSULOSIN 0.4 MG + DUTASTERIDE 0.5 MG TABLETS	15's	15'sx10	15'sx10x10	44000
183	572	COMBINATIONS WITH TETANUS COMPONENT (DIPHThERIA, TETANUS, PERTUSSIS, POLIOMYELITIS AND HAEMOPHILUS INFLUENZA) INJECTION	0.5 ML	0.5 ML X10	0.5 MLX10X50	40000
184	573	MONOCLONAL ANTI-D GAMAGLOBULIN INJECTION 300 MCG	1 ML with WFI	1'sX10	1'sX10X50	11000
185	575	VACCINE VARICELLA INJECTION	0.5 ML	0.5 ML X10	0.5 MLX10X50	15000
186	576	VACCINE HEPATITIS A INJECTION 80 IU	5 ML	5 ML X10	5 ML X10X50	13000
187	577	VACCINE STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE INJECTION 0.5 ML	0.5 ML	0.5 MLX10	0.5 MLX10X100	11000
188	578	VACCINE ROTA VIRUS LIVE ORAL	1 ML	1'sX10	1'sX10X100	20000
189	579	CALCIUM PANTOTHENATE 50MG+VIT B12 15 MCG+FOLIC ACID 1.5MG+THIAMINE MONONITRATE	20's	20'sX10	20'sx10x10	2971000

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Pack Size	Packing per carton specification	Approx. tender qty.
		10MG+RIBOFLAVINE 10MG+PYRIDOXINE HCL 3 MG+NIACINAMIDE 100 MG+ASCORBIC ACID 150MG +BIOTIN 100MCG CAPSULES				
190	580	ginseng extract 42.5 mg, vitamin A 2500 IU, vitamin B1 1 mg, vitamin B2 1.5 mg, vitamin B6 1 mg, vitamin B12 1 mcg, vitamin C 50 mg, vitamin E 5 mg, vitamin D 200 IU, nicotinamide 10 mg, carbohydrates 0.1 g, folic acid 0.15 mg, ferrous fumarate 30 mg, copper 0.5 mg, potassium sulphate 2 mg, manganese 0.5 mg, magnesium sulphate 3 mg, zinc oxide 10 mg, calcium 75 mg, phosphate 58 mg, iodine 0.1 mg, protein 0.2 g, fat 0.38 g	10's	10'sx10	10'sx10x10	451000
191	581	CALCIUM CARBONATE 500 MG + CALCITRIOL 0.25 MCG + ZINC 7.5 MG	15's	15'sx10	15'sx10x10	113000
192	582	VITAMINS A,C,D,E,AND B COMPLEX AND MINERALS SYRUP	200 ML	1's	200 ML X 20	184000
193	584	CALCIUM CITRATE MALATE 250 MG , VITAMIN D3 100 IU AND FOLINIC ACID 50 MCG TABLETS	30's	30'Sx10	30'Sx10x10	171000
194	586	METHYLCOBALAMIN 1500 MCG, L- CARTININE L- TARTRATE 500 MG, FOLIC ACID 1.5 MG TABLETS	10's	10'sx10	10'sx10x10	100000
195	587	APPETITE ENHANCER (PEPTONE, MINERALS, VITAMINS)SYRUP	300 ML	1's	1's X 20	172000
196	588	VITAMIN E SOFTGEL CAPSULES 400 MG	10's	10'sx10	10'sx10x10	483000
197	590	VITAMIN A,B COMPLEX,D,E INJECTION	10 ML VIAL	10 MLX10	10 MLX10X20	498000
198	591	METHYLCOBALAMIN 500 MCG INJECTION	1 ML AMPULE	1 MLX10	1 MLX10X100	115000
199	592	L-LYSINE + MULTIVITAMINS (VIT-B1,B2,B3,B5,B6) SYRUP	200 ML	1's	200 ML X 20	207000
200	593	NICOTINAMIDE 200 MG+ FOLIC ACID 15 MG + CYANOCOBALAMIN 0.5 MCG INJECTION	10 ML	10 MLX10	10 MLX10X20	109000
201	594	GLUCOSE D POWDER	100 GM	100 GM	100 GMX40	22000
202	595	THIAMINE 100 MG+ PYRIDOXINE HCl 50 MG + CYANOCOBALAMIN 1000 MCG INJECTION	2 ML	2 ml x 10	2 ml x 10 x 50	602000
203	596	ZINC SULPHATE 20 MG/ ML ORAL SOLUTION	15 ML	15 ML x20	15 ML x20 X20	40000
204	597	VITAMIN B6 TABLETS IP 5 MG	10's	10'sx10	10'sx10x10	147000
205	599	PREGABALIN TABLETS 75 MG	10's	10'sx10	10'sx10x10	120000

ANNEXURE -XIV

Ref. Clause No.10.1

Performance Security Bank Guarantee

(unconditional)

To: Bureau of Pharma Public Sector Undertakings of India, (Name of purchaser) IDPL Complex, Old-Delhi-Gurgaon Road, Dundehera, Gurgaon 122016 (Haryana)

WHEREAS.....(Name of the Supplier) herein called “the Supplier” has undertaken, in pursuance of Tender BPPI/DRUGS/025/2015 dated **13.07.2015** to supply of **Drugs and Medicines for the year 2015-17**, (Description of Goods and Services) hereinafter called “the Contract”.

AND WHEREAS it has been stipulated by you in the said Contract that the Supplier shall furnish you with a Bank Guarantee for the sum specified therein as security for compliance with the Supplier’s performance obligations in accordance with the Contract.

AND WHEREAS we have agreed to give the Supplier a Guarantee

THEREFORE WE hereby affirm that we are Guarantors and responsible to you, on behalf of the Supplier, upto a total of(Amount of the Guarantee in Words and Figures) and we undertake to pay you, upon your first written demand declaring the Supplier to be in default under the Contract and without cavil or argument., any sum or sums within the limit of(Amount of the Guarantee in Words and Figures) as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

This guarantee is valid until theday of.....2017.

Signature and Seal of Guarantors

.....
.....
.....

Date.....2015

Address.....

.....

ANNEXURE-XV

Ref. Clause No.10.2

AGREEMENT

THIS AGREEMENT made theday of2015 Between
Bureau of Pharma Public Sector Undertakings of India, IDPL Complex, Old-Delhi Gurgaon
Road, Dundahera, Gurgaon 122016 (Haryana)

(Name of purchaser) of (Country of Purchaser) (here in after “the Purchaser”) of the
one part and(Name of Supplier) of
.....(City and Country of Supplier) (herein after called
“the Supplier”) of the other part :

WHEREAS the Purchaser is desirous that certain Goods and ancillary services viz;
Supply of Drugs and Medicines in the tender Reference No. BPPI/DRUGS/025/2015 (Brief
Description of Goods and Services) and has accepted a bid by the Supplier for the supply of
those goods and services for the sum of(Contract Price in
Words and Figures(hereinafter called “the Contract Price”).

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. In this Agreement words and expressions shall have the same meanings as are
respectively assigned to them in the Conditions of Contract referred to, and they shall
be deemed to form and be read and construed as part of this agreement.
2. The following documents shall be deemed to form and be read and construed as part
of this Agreement, viz
 - a. The Letter of Acceptance issued by the purchaser.
 - b. The Notice Inviting Tender
 - c. The supplier’s bid including enclosures, annexures, etc.
 - d. The Terms and Conditions of the Contract
 - e. The Schedule of Requirement

- f. The Technical Specification
 - g. Any other document listed in the supplier's bid and replies to queries, clarifications issued by the purchaser, such confirmations given by the bidder which are acceptable to the purchaser and the entire Addendum issued as forming part of the Contract.
3. In consideration of the payments to be made by the Purchaser to the Supplier as hereinafter mentioned, the Supplier hereby covenants with the Purchaser to provide, the goods and services and to remedy defects therein in conformity in all respects with the provisions of the Contract. .
 4. The purchaser hereby covenants to pay the Supplier in consideration of the provision of the goods and services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of the Contract at the times and in the manner prescribed by the Contract.

Brief particulars of the goods and services which shall be supplied / provided by the Supplier are as under:

S.No.	Drug Code	Brief Description of Goods & Services	Tender Qty in Unit*	Unit Price	CST/VAT in %	Total (B+C)	Total value inclusive ST/VAT (Ax D)
			(A)	(B)	(C)	(D)	
Total Contract Value							

- * **Tender quantity indicated here is tentative and may vary subjected to various terms and conditions of the tender.**
- * **Excise duty as applicable on MRP to be intimated by BPPI at the time of placing orders will be payable as per prevailing excise duty rates.**

DELIVERY SCHEDULE

Supply shall all complete within 60th day from the date of issue of Ist purchase order and within 45th day from the date of issue of subsequent purchase order.

IN WITNESS where of the parties here to have caused this Agreement to be executed in accordance with their respective laws the day and year first above written.

Signed, Sealed and Delivered by the

Said.....(For the Purchaser)

Name

Address

Designation

In the presence of witness.....

Signature

Name

Address

Designation

Signed, Sealed and Delivered by the

Said.....(For the Supplier)

Name

Address

Designation

In the presence of witness

Signature

Name

Address Designation

ANNEXURE-XVI

Ref. Clause No.14.1

SCHEDULE FOR PACKAGING OF DRUGS AND MEDICINES

GENERAL SPECIFICATIONS

1. Strips of Aluminum foils should be gauge 04.
2. Aluminum foils s back material for blisters should be gauge 025.
3. The rigid PVC used in blister packing should be of not less than 250 micron
4. All glass bottles should be new neutral glass. Pet bottles so accepted as per drug laws stipulation.
5. Ointments should be packed in lacquerized Aluminum Tubes or Lami tubes.
6. Small Tablets packed in blisters should be packed to facilitate easy removal of the tablet without breaking / crushing.
7. Specification of outer cartons are as given in the Schedule (Annexure-XIV)
8. In case of any conflict between Carton specifications and packets per carton specification the specification of the packets / carton shall prevail.
9. All plastic containers should be made of virgin grade plastics
10. Injection in vials should have a flip-off seals.
11. The strips shall be aluminum strip / blisters with aluminum foil back.
12. The minimum diameters of each tablets should be of 6.4mm
13. The outer carton should be of white board with a minimum of 300 GSM with **Gloss laminated/UV Varnished** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with white board of 350GSM.
14. All liquid oral preparations to be provided with a measuring plastic cup, fitted over the cap of the bottle.
15. All primary packaging should have BPPI toll free number 1800 180 8080

(Schedule)

1.	CORRUGATED BOXES(Liquid) <ol style="list-style-type: none">1. No corrugate package should weigh more than 15 kgs (i.e. product + inner carton + corrugated box).2. All Corrugated boxes should be of 'A' grade paper i.e. Virgin.3. All items should be packed only in first hand boxes only.
----	--

2.	FLUTE
	The corrugated boxes should be of narrow flute.
3.	JOINT
	Every box should be preferably single joint and not more than two joints.
4.	STITCHING
	Every box should be stitched using pairs of metal pins with an interval of two inches between each pair. The boxes should be stitched and not joined using calico at the corners.
5.	FLAP
	The flaps should uniformly meet but should not over lap each other. The flap when turned by 45 - 60° should not crack.
6.	TAPE
	Every box should be sealed with gum tape running along the top and lower opening.
7.	CARRYSTRAP:
	Every box should be strapped with two parallel nylon carry straps (they should intersect).
8.	LABEL
	The product label on the carton should be large at least 15 cms x 10 cms dimension. It should carry the correct technical name, strength of the product, date of manufacturing, date of expiry, quantity packed and net weight of the box.
9.	OTHERS
	No box should contain mixed products or mixed batches of the same product.

II. SPECIFICATION OF CORRUGATED BOXES HOLDING TABLETS / CAPSULES / PESSARIES

- (1) The box should not weigh more than 7-8 kgs. The grammage of outer box should be 150 gsm and inside partition / lining should be 120 gsm.
- (2) The box should be of 5 ply with bursting strength of 9 Kg / Cm²

III. SPECIFICATIONS OF CORRUGATED BOXES FOR OINTMENT / CREAM / GELS PACKED IN TUBES:

- (1) No corrugate box should weigh more than 7-8 Kgs.
- (2) Every Ointment tube should be individually packed in carton and then packed in 20's in a grey board box, which may be packed in a corrugated box.
- (3) Grammage: Outer box should be 150 gsm inside partition /
Lining should be 120gsm.

IV. SPECIFICATIONS OF CORRUGATED BOXES FOR INJECTABLE (IN VIALS AND AMPOULES)

- (1) Vials may be packed in corrugated boxes weighing upto 15 Kgs. Ampoules should be packed in C.B weighing not more than 8 kgs.
- (2) C.B. for vials should be of 150 gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 7 ply, while CB. For ampoules should be of 150 gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 5 ply.
- (3) Bursting strength for CB boxes for
 - i. Vials : Note less than 13 Kg/Cm²
 - ii. Amp : Note less than 9 Kg/Cm²
- (4) In the case of 10 ml Ampoules 100 or 50 ampoules may be packed in a grey board box. Multiples of grey board boxes packed in CB. In case of ampoules larger than 10 ml only 25 ampoules may be packed in a grey board box with partition.
- (5) If the vial is packed in individual carton, there is no necessity for grey board box packing. The individual carton may be packed as such in the CB with center pad.
- (6) In case of ampoules every grey board box should carry 5 amps. Cutters placed in a polythene bag.
- (7) Vials of eye and ear drops should be packed in an individual carton with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a grey board box.

ANNEXURE -XVII

Ref. clause 16.2

MANDATE FORM

Sl.No.	Details Required	
1.	Company Name	
2.	Postal Address of the Company	
	Telephone No.	
	Fax No.	
	E-mail ID	
3.	Name of the Managing Director / Director / Manager	
	Mobile No. / Phone No	
	E-mail ID	
4.	Name and Designation of the authorized company official	Name:
		Designation:
	Mobile No.	
	E-mail ID	
5.	Bank Details	
	a) Name of the Bank	
	b) Branch Name & address	
	c) Branch Code No.	
	d) Branch Manager Mobile No.	
	e) Branch Telephone no	
	f) Branch E-mail ID	
	g) 9 digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank	
	h) IFSC Code of the Branch	
	i) Type of Account (Current / Savings)	
	j) Account Number (as appear in cheque book)	

(In lieu of the bank certificate to be obtained, please **attach the original cancelled cheque** issued by your bank for verification of the above particulars).

I / We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all the reasons of incomplete or incorrect information, I would not hold Bureau of Pharma Public Sector Undertakings of India (BPPI) responsible. I have read the conditions of the tender / agreement entered and agree to discharge the responsibility expected of me / from the company as a tenderer / successful tenderer.

Date:

Company Seal

Signature

Place:

(Name of the person signing & designation)

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Signature of the authorized official of the bank

Bank Seal with address:

ANNEXURE –XVIII

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA											
GURGAON(HR)											
TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015											
Break up of Landed Price											
Note 1: The firms should indicate breakup prices at column 5 to 8 and 10 to 12 separately and working like "included" should not be substituted for the same as per specification laid down in relevant Pharmacopoeias.											
Note 2: For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.											
*As per stated formulation /Combination is fixed but strength may vary											
Sl. No	Drug code	Generic Name of the Medicines	Unit Size	Basic price Inclusive of incidental services	Bar coding charges	Packing and Forwarding Charges	Freight and insurance charges	Total landed prices	Rate of		Cen. Excise duty applicable (Y/N)
									CST %	VAT %	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
1	14	Ibuprofen 400 mg+ Paracetamol 325 mg Tabs.	10's								
2	15	Ibuprofen 200 mg Tabs.	10's								
3	16	Ibuprofen 400 mg Tabs.	10's								
4	25	Serratiopeptidase Tablets 10 mg	10's								
5	53	Cefixime Oral Suspension IP 50 mg/5 ml	30 ml bottle								
6	60	CEFOTAXIME SODIUM 250 MG & SULBACTAM SODIUM 125 MG INJECTION	VIAL & WFI								
7	83	CIPROFLOXACIN 250 MG+ TINIDAZOLE 300 MG FILM COATED TABLETS	10's								
8	89	CO-TRIMOXAZOLE TABLETS IP (160 MG + 800 MG)	10's								
9	112	BECLOMETHASONE IP 0.025% w/w+ CLOTRIMAZOLE IP 1% w/w+ GENTAMYCIN IP 0.1% w/w CREAM	15 GM								
10	115	Calamine lotion 100 ml	100ml bottle								
11	127	Povidone Iodine 5% Solution 100ml	100ml bottle								
12	143	BIPHASIC INSULIN ASPART INJECTION IP 100 IU/ML (30:70)	VIAL								
13	144	METFORMIN HYDROCHLORIDE SUSTAIN RELEASE TABLETS IP 1000 MG	10's								

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Break up of Landed Price

Note 1: The firms should indicate breakup prices at column 5 to 8 and 10 to 12 separately and working like "included" should not be substituted for the same as per specification laid down in relevant Pharmacopoeias.

Note 2: For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

*As per stated formulation /Combination is fixed but strength may vary

Sl. No	Drug code	Generic Name of the Medicines	Unit Size	Basic price Inclusive of incidental services	Bar coding charges	Packing and Forwarding Charges	Freight and insurance charges	Total landed prices	Rate of		Cen. Excise duty applicable (Y/N)
									CST %	VAT %	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
14	153	CISPLATIN INJECTION IP 10 MG	VIAL & WFI								
15	165	CIPROFLOXACIN INJECTION IP 2MG/ML	100 ML								
16	191	FAMOTIDINE TABLETS IP 20 MG	14's								
17	192	FAMOTIDINE TABLETS IP 40 MG	14's								
18	194	Hyoscine Butyl Bromide film coated tablet 10 mg	10's								
19	196	LACTOBACILLUS SPOROGENES 60 MILLION SPORES TABLETS	10's								
20	201	METRONIDAZOLE 200 MG FILM COATED TABLETS	10'S								
21	202	METRONIDAZOLE 400 MG FILM COATED TABLETS	10'S								
22	208	ONDENSETRON INJECTION IP 2 mg/ml	2 ML								
23	213	Pantoprazole 40mg/10ml Inj.	vial								
24	216	RANITIDINE INJECTION IP 50 MG/ 2ML	2 ML								
25	225	IRON HYDROXIDE POLYMALTOSE COMPLEX EQ TO ELEMENTAL IRON 50 MG+ FOLIC ACID 0.5 MG /5 ML SYRUP	200 ML								
26	229	Haematinic Syrup of Iron , acid and Vitamin B12 100ml	100ml bottal								
27	230	VITAMIN B COMPLEX (B1,B2,B6,B12) & VIT. C WITH ZINC 22.5 MG CAPSULES	10's								
28	231	VITAMIN B1 10MG, B2 10 MG, NIACINAMIDE 45 MG, CALCIUM PANTOTHENATE 50 MG, B6 3 MG AND B12 15 MCG TABLETS	10's								
29	232	VITAMIN B-VOMPLEX Syrup NFI	200 ML								
30	235	BUDESONIDE RESPULES 0.5 MG	2 ML								

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Break up of Landed Price

Note 1: The firms should indicate breakup prices at column 5 to 8 and 10 to 12 separately and working like "included" should not be substituted for the same as per specification laid down in relevant Pharmacopoeias.

Note 2: For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

*As per stated formulation /Combination is fixed but strength may vary

Sl. No	Drug code	Generic Name of the Medicines	Unit Size	Basic price Inclusive of incidental services	Bar coding charges	Packing and Forwarding Charges	Freight and insurance charges	Total landed prices	Rate of		Cen. Excise duty applicable (Y/N)
									CST %	VAT %	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
31	241	COUGH SYRUP DEXTROMETHORPHAN HBR10 mg+ CPM 4 MG /10 ML SYRUP	100 ML								
32	244	THEOPHYLLINE 25.3 MG+ ETOPHYLLINE 84.6MG INJECTION 2 ML	2 ML								
33	255	SALBUTAMOL INHALATION IP 100 µg/ METERED DOSE	200 MD								
34	256	salbutamol 2mg tablets	10x10								
35	278	FRUSEMIDE INJECTION IP (10 MG/ ML)	2 ML								
36	285	AMLODIPINE 5 MG + LISINOPRIL 5 MG TABLETS	15's								
37	302	TRANEXAMIC ACID 500 MG/5 ML	5 ML AMPU LE								
38	306	PRIMAQUINE TABLETS IP 15 MG	7's								
39	323	FLUNARZINE TABLETS 10MG	10's								
40	324	FLUNARZINE TABLETS 5MG	10's								
41	329	PREDNISOLONE TABLETS IP 5 MG	15's								
42	331	THYROXINE SODIUM TABLETS IP 50 µg	10's								
43	333	dexamethazone 0.5 mg Tablets	10x10								
44	334	DEXAMETHASONE INJECTION IP 4 MG/ML	2 ML								
45	338	ATROPINE SULPHATE INJECTION IP 0.6MG/ ML	1 ML								
46	341	CARBOXY METHYL CELLULOSE EYE DROPS IP 0.5% w/v	10 ML								
47	344	Ciprofloxacin 0.3% w/V Eye drops	5ml								
48	345	gentamycin 0.3 % w/V eye drops	5ml								
49	356	LIGNOCAINE INJECTION IP 2% w/v	20 ML VIAL								
50	357	Ligncaine 1% + adrenaline 2% W/V inj.	30 ml vial								
51	358	Propafol 10mg/ ml Inj	10ml vial								
52	359	TETANUS VACCINE (Adsorbed) IP	AMP 0.5 ML								

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Break up of Landed Price

Note 1: The firms should indicate breakup prices at column 5 to 8 and 10 to 12 separately and working like "included" should not be substituted for the same as per specification laid down in relevant Pharmacopoeias.

Note 2: For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

*As per stated formulation /Combination is fixed but strength may vary

Sl. No	Drug code	Generic Name of the Medicines	Unit Size	Basic price Inclusive of incidental services	Bar coding charges	Packing and Forwarding Charges	Freight and insurance charges	Total landed prices	Rate of		Cen. Excise duty applicable (Y/N)
									CST %	VAT %	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
53	361	OXYTOCIN INJECTION IP 5 UNITS/ML	1 ML								
54	362	BIPHASIC ISOPHANE INSULIN INJECTION IP 40 IU/ML (50:50)	10 ML VIAL								
55	366	GLIPIZIDE 5 MG + METFORMIN HYDROCHLORIDE 500 MG TABLETS	10's								
56	368	GLICLAZIDE TABLETS SR 60 MG	10's								
57	369	ACARBOSE TABLETS IP 50 MG	10's								
58	370	NEUTRAL PROTAMINATED HAGEDORN INJECTION 40 IU	10 ML VIAL								
59	372	METFORMIN HYDROCHLORIDE TABLETS IP PROLONG RELEASE 500 MG	10's								
60	373	ARTESUNATE INJECTION 60 MG	1 ML								
61	374	ARTEMETHER 80 MG + LUMEFANTRINE 480 MG SR TABLETS	6's								
62	375	QUININE TABLETS IP 300 MG FILM COATED TABLETS	10's								
63	377	CLINDAMYCIN CAPSULES IP 300 MG	10's								
64	378	EACH KIT CONTAIN RIFAMPICIN TABLET IP 450MG, ISONIAZIDE TABLET IP 300MG ETHAMBUTOL TABLET IP 800MG AND PYRAZINAMIDE TABLETS IP 750MG	1's								
65	379	RIFAMPICIN and ISONIAZIDE TABLETS IP (450 MG+300 MG)	10's								
66	382	LINEZOLID TABLETS IP 600 MG	10's								
67	387	TERBINAFINE 250 MG TABLETS	7's								
68	388	EACH KIT CONTAIN RIFAMPICIN TABLET IP 450MG, ISONIAZIDE TABLET IP 300MG and ETHAMBUTOL TABLET IP 800MG	1's								

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Break up of Landed Price

Note 1: The firms should indicate breakup prices at column 5 to 8 and 10 to 12 separately and working like "included" should not be substituted for the same as per specification laid down in relevant Pharmacopoeias.

Note 2: For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

*As per stated formulation /Combination is fixed but strength may vary

Sl. No	Drug code	Generic Name of the Medicines	Unit Size	Basic price Inclusive of incidental services	Bar coding charges	Packing and Forwarding Charges	Freight and insurance charges	Total landed prices	Rate of		Cen. Excise duty applicable (Y/N)
									CST %	VAT %	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
69	389	PENICILLIN G 400000 IU TABLETS	6's								
70	390	ETHAMBUTOL TABLETS IP 800 MG	10's								
71	391	MOXIFLOXACIN TABLETS 400 MG	5's								
72	392	GRISEOFULVIN TABLETS IP 250 MG	10's								
73	393	ACICLOVIR DISPERSIBLE TABLETS IP 800 MG	5's								
74	394	PYRANTEL PAMOATE ORAL SUSPENSION IP 250 MG/10 ML	10 ML								
75	396	AMPHOTERICIN B INJECTION IP. 50MG/ML	20 ML								
76	397	OXYTETRACYCLINE CAPSULES IP 250 MG	8's								
77	398	RIFAMPICIN TABLETS IP 450 MG	10's								
78	399	RIFAMPICIN, ISONIAZIDE and PYRAZINAMIDE TABLETS IP (120MG+50MG+300MG)	10's								
79	403	CLINDAMYCIN INJ IP 300 MG/2 ML	2 ML								
80	404	LINEZOLID INFUSION 600 MG/300 ML	300 ML								
81	406	ACICLOVIR INTRAVENOUS INFUSION IP 500 MG/VIAL	VIAL								
82	407	IVERMECTIN TABLETS 12 MG	10's								
83	408	BENZYL PENICILLIN INJECTION IP 0.6 MILLION UNITS	VIAL								
84	409	BENZYL PENICILLIN INJECTION IP 1.2 MILLION UNITS	VIAL								
85	410	TRASTUZUMAB INJECTION 440 MG with WFI	1's								
86	411	BEVACIZUMAB INJECTION 25 MG	1's								
87	412	AZATHIOPRINE TABLETS IP 50 MG	10's								
88	413	METHOTREXATE TABLETS IP 7.5 MG	10's								

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Break up of Landed Price

Note 1: The firms should indicate breakup prices at column 5 to 8 and 10 to 12 separately and working like "included" should not be substituted for the same as per specification laid down in relevant Pharmacopoeias.

Note 2: For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

*As per stated formulation /Combination is fixed but strength may vary

Sl. No	Drug code	Generic Name of the Medicines	Unit Size	Basic price Inclusive of incidental services	Bar coding charges	Packing and Forwarding Charges	Freight and insurance charges	Total landed prices	Rate of		Cen. Excise duty applicable (Y/N)
									CST %	VAT %	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
89	415	GLYCERYL TRINITRATE TABLETS IP 250 µg	25's								
90	416	PRazosin TABLETS IP 5 MG	15's								
91	419	HEPARIN SODIUM 50 IU/20 GM OINTMENT	20 GM								
92	420	ATORVASTATIN 10 MG+ CLOPIDOGREL 75 MG CAPSULES	10's								
93	421	NEBIVOLOL TABLETS IP 5 MG	10's								
94	423	BISOPROLOL TABLETS 5 MG	10's								
95	424	CARVEDILOL TABLETS IP 3.125 MG	10's								
96	425	DILTIAZEM TABLETS SR 90 MG	10's								
97	426	ACENOCOUMAROL TABLETS 2 MG	30's								
98	427	S-AMLODIPINE TABLETS IP 2.5 MG	10's								
99	431	RAMIPRIL and HYDROCHLORTHIAZIDE TABLETS IP (5MG+12.5 MG)	10's								
100	433	ISOSORBIDE MONONITRATE TABLETS IP 30 MG	30's								
101	438	INDAPAMIDE TABLETS IP 1.5 MG	10's								
102	440	METOPROLOL 50 MG + AMLODIPINE 5 MG TABLETS	7's								
103	441	LOSARTAN 50 MG+ AMLODIPINE 5 MG TABLETS	10's								
104	442	FENOFIBRATE CAPSULES IP 150 MG	10's								
105	443	ISOSORBIDE DINITRATE TABLETS IP 5 MG	50's								
106	444	ENALAPRIL 10 MG + HYDROCHLORTHIAZIDE 25 MG TABLETS	30's								
107	446	AMLODIPINE 5 MG + HYDROCHLOROTHIAZIDE 12.5 MG TABLETS	10's								
108	447	MOXONIDINE TABLETS 0.3 MG	10's								
109	448	AMLODIPINE 5 MG+ RAMIPRIL 5 MG	10's								

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Break up of Landed Price

Note 1: The firms should indicate breakup prices at column 5 to 8 and 10 to 12 separately and working like "included" should not be substituted for the same as per specification laid down in relevant Pharmacopoeias.

Note 2: For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

*As per stated formulation /Combination is fixed but strength may vary

Sl. No	Drug code	Generic Name of the Medicines	Unit Size	Basic price Inclusive of incidental services	Bar coding charges	Packing and Forwarding Charges	Freight and insurance charges	Total landed prices	Rate of		Cen. Excise duty applicable (Y/N)
									CST %	VAT %	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
		TABLETS									
110	449	SPIRONOLACTONE TABLETS IP 25 MG	15's								
111	450	LABETALOL TABLETS IP 100 MG	10's								
112	452	WARFARIN TABLETS IP 5 MG	10's								
113	453	BISOPROLOL 5 MG+ HYDROCHLOROTHIAZIDE 6.25 MG TABLETS	10's								
114	454	VALSARTAN TABLETS IP 80 MG	10's								
115	455	VERAPAMIL TABLETS IP 80 MG	10's								
116	457	TORASEMIDE TABLETS 20 MG	10's								
117	461	BETAMETHASONE VALERAT 0.1 % w/w + NEOMYCIN SULFATE 0.5 % w/w CREAM	20 GM								
118	462	BETAMETHASONE VALERATE and CLIOQUINOL CREAM BP (0.12w/w+3%w/w)	30 GM								
119	464	DICYCLOMINE 10 MG + PARACETAMOL 325 MG + TRAMADOL 50 MG CAPSULES	10's								
120	468	BACILLUS CLAUSII SPORES ORAL SUSPENSION 2 Billion/ 5 ML	5 ML								
121	469	HEPATIC PROTECTORS SYRUP	200 ML								
122	470	PEPSIN 10 MG+ DIASTASE 50 MG ORAL LIQUID /5 ML	200 ML								
123	471	OXETACAINE 10 MG+ ALUMINIUM 291 MG + MAGNESIUM 98 MG /5 ML GEL	200 ML								
124	472	DOMPERIDONE 30 MG+ ESOMEPRAZOLE 40 MG CAPSULE	10's								
125	473	LEVOSULPIRIDE 75 MG+ PANTOPRAZOLE 40 MG CAPSULE	10's								
126	476	LIQUID PARAFFIN 1.25 ML+ MILK OF MAGNESIA 3.75ML+ SODIUM PICOSULPHATE 3.33MG	200 ML								

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Break up of Landed Price

Note 1: The firms should indicate breakup prices at column 5 to 8 and 10 to 12 separately and working like "included" should not be substituted for the same as per specification laid down in relevant Pharmacopoeias.

Note 2: For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

*As per stated formulation /Combination is fixed but strength may vary

Sl. No	Drug code	Generic Name of the Medicines	Unit Size	Basic price Inclusive of incidental services	Bar coding charges	Packing and Forwarding Charges	Freight and insurance charges	Total landed prices	Rate of		Cen. Excise duty applicable (Y/N)
									CST %	VAT %	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
		/5ML EMULSION									
127	477	CLIDINIUM 2.5 MG+ CHLORDIAZEPOXIDE 5 MG FILM COATED TABLETS	15's								
128	479	TRICHOLINE CITRATE 550 MG + SORBITOL 7.15 MG SYRUP/5 ML	200 ML								
129	480	LEVOSULPIRIDE 75 MG+ ESOMEPRazole 40 MG CAPSULES	10's								
130	481	RIFAXIMIN TABLETS BP 40 MG	10's								
131	486	PANCREATIN 170 MG+ DIMETHICONE 80 MG TABLETS	10's								
132	487	DICYCLOMINE 10 MG + DIMETHICONE 40 MG /5 ML SUSPENSION	30 ML								
133	488	LANSOPRAZOLE CAPSULES IP 15 MG	10's								
134	489	SULFASALAZINE TABLETS BP 1000 MG ENTERIC COATED	10's								
135	490	SIMETHICONE 40 MG DROPS	15 ML								
136	492	SULFASALAZINE TABLETS BP 500 MG ENTERIC COATED	10's								
137	493	ISPAGHULA HUSK IP 50 GM	50 GM								
138	494	ISPAGHULA HUSK IP 100 GM	100 GM								
139	495	FERROUS AMMONIUM CITRATE 160 MG + CYANO COBALAMINE 7.5 MCG + FOLIC ACID 0.5 MG/15ML SYRUP	200 ML								
140	496	DYDROGESTERONE TABLETS IP 10 MG	10's								
141	498	FERROUS ASCORBATE 100MG WITH FOLIC ACID 1.5MG TABLETS	10's								
142	500	LEVO-THYROXINE TABLETS IP 100 MCG	100's in A Bottle								
143	501	BETAMETHASONE SODIUM PHOSPHATE TABLETS IP 0.5 MG	20's								
144	503	METHYLPREDNISOLON E SODIUM SUCCINATE INJECTION 1000 MG	VIAL & WFI								

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Break up of Landed Price

Note 1: The firms should indicate breakup prices at column 5 to 8 and 10 to 12 separately and working like "included" should not be substituted for the same as per specification laid down in relevant Pharmacopoeias.

Note 2: For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

*As per stated formulation /Combination is fixed but strength may vary

Sl. No	Drug code	Generic Name of the Medicines	Unit Size	Basic price Inclusive of incidental services	Bar coding charges	Packing and Forwarding Charges	Freight and insurance charges	Total landed prices	Rate of		Cen. Excise duty applicable (Y/N)
									CST %	VAT %	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
		PER VIAL									
145	504	NANDROLONE DECANOATE INJECTION IP 25MG/ML	2 ML								
146	505	CARBIMAZOLE TABLETS IP 10 MG	100's in Bottle								
147	506	LEVO-THYROXINE TABLETS IP 50 MCG	100's in Bottle								
148	507	CARBIMAZOLE TABLETS IP 5 MG	10's								
149	514	CHYMOTRYPSIN + TRYPSIN (1:6)ENTERIC COATED TABLETS 100K AU	20's								
150	519	KETOROLAC TABLETS DT 10 MG	10's								
151	520	MEFENAMIC ACID 500 MG+ PARACETAMOL 325 MG TABLETS	10's								
152	521	TRAMADOL TABLETS SR 100 MG	10's								
153	522	ALFACALCIDOL SOFT GELATIN CAPSULES 0.25 MCG	10's								
154	523	NAPROXEN TABLETS IP 500 MG	15's								
155	524	LIDOCAINE INJECTION IP 2 % W/V	30 ML VIAL								
156	526	CHLORPHENIRAMINE 4 MG+ CODEINE 10 MG/5 ML SYRUP	100 ML								
157	527	AMMONIUM CHLORIDE 50 MG+ CHLORPHENIRAMINE MALEATE 2.5 MG+ DEXTROMETHORPHAN 5 MG+ GUAIFENESIN 50 MG / 5ML SYRUP	100 ML								
158	529	LEVOSALBUTAMOL 1.25 MCG+ IPRATROPIUM 500 MCG RESPULES/2.5ML	2.5 ML								
159	530	FORMOTEROL 6 MG+ BUDESONIDE 200 MG ROTACAP	30's								
160	532	SALMETEROL 50 MG+ FLUTICASONE 250 MG ROTACAP	30's								
161	534	SALBUTAMOL 200 MCG + BECLOMETHASONE 100 MCG ROTACAP	30's								

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Break up of Landed Price

Note 1: The firms should indicate breakup prices at column 5 to 8 and 10 to 12 separately and working like "included" should not be substituted for the same as per specification laid down in relevant Pharmacopoeias.

Note 2: For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

*As per stated formulation /Combination is fixed but strength may vary

Sl. No	Drug code	Generic Name of the Medicines	Unit Size	Basic price Inclusive of incidental services	Bar coding charges	Packing and Forwarding Charges	Freight and insurance charges	Total landed prices	Rate of		Cen. Excise duty applicable (Y/N)
									CST %	VAT %	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
162	535	TERBUTALINE 2.5 MG + BROMHEXINE 8 MG /10 ML SYRUP	100 ML								
163	536	PROMETHAZINE 1.5 MG + PHOLCODINE CITRATE 1.5 MG /5ML LINCTUS	60 ML								
164	537	SALBUTAMOL 1 MG+ AMBROXOL HYDROCHLORIDE 15 MG/5 ML SYRUP	100 ML								
165	538	THEOPHYLLINE TABLETS 400 MG	10's								
166	540	LEVBUTEROL 1.25 MG+ BUDESONIDE 1MG REPSULE	2 ML								
167	543	MENTHOL CINNAMON and PINE OIL SOFT CAPSULES	10's								
168	544	FLUTICASONE PROPIONATE RESPULE 0.5 MG/2ML	2 ML								
169	555	DOXOFYLLINE TABLETS IP 400 MG	10's								
170	556	MONTELUKAST 10 MG + FEXOFENADINE 120 MG TABLETS	10's								
171	557	TIOTROPIUM ROTOCAP 18 MCG	15's								
172	558	FLUTICASONE 50 MCG+ AZELASTINE 140 MCG NASAL SPRAY	120MD								
173	559	SALBUTAMOL 2MG + THEOPHYLLINE 100 MG TABLETS	30's								
174	560	FLUTICASONE PROPIONATE 50 MCG PER PUFF NASAL SPRAY	120 MD								
175	561	LEVOSALBUTAMOL 1 MG/5ML SYRUP	100 ML								
176	563	OXYMETAZOLINE 0.5 MG /ML NASAL DROPS	10 ML								
177	564	FORMOTEROL 12 MG + TIOTROPIUM 18 MG ROTOCAP	15's								
178	565	CICLESONIDE 400 MCG+ FORMOTEROL 12 MCG + TIOTROPIUM 18 MCG ROTOCAP	15's								
179	566	IPRATROPIUM 250 MCG/ML I:SOLUTION	15 ML								

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Break up of Landed Price

Note 1: The firms should indicate breakup prices at column 5 to 8 and 10 to 12 separately and working like "included" should not be substituted for the same as per specification laid down in relevant Pharmacopoeias.

Note 2: For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

*As per stated formulation /Combination is fixed but strength may vary

Sl. No	Drug code	Generic Name of the Medicines	Unit Size	Basic price Inclusive of incidental services	Bar coding charges	Packing and Forwarding Charges	Freight and insurance charges	Total landed prices	Rate of		Cen. Excise duty applicable (Y/N)
									CST %	VAT %	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
180	567	SALBUTAMOL 100 MCG + IPRATROPIUM 20 MCG /PUFF INHALER	100 MD								
181	568	SALMETEROL 50 MCG+ FLUTICASON PROPRIONATE 250 MCG /PUFF INHALER	100 MD								
182	571	TAMSULOSIN 0.4 MG + DUTASTERIDE 0.5 MG TABLETS	15's								
183	572	COMBINATIONS WITH TETANUS COMPONENT (DIPHTHERIA, TETANUS, PERTUSSIS, POLIOMYELITIS AND HAEMOPHILUS INFLUENZA) INJECTION	0.5 ML								
184	573	MONOCLONAL ANTI-D GAMAGLOBULIN INJECTION 300 MCG	1 ML with WFI								
185	575	VACCINE VARICELLA INJECTION	0.5 ML								
186	576	VACCINE HEPATITIS A INJECTION 80 IU	5 ML								
187	577	VACCINE STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE INJECTION 0.5 ML	0.5 ML								
188	578	VACCINE ROTA VIRUS LIVE ORAL	1 ML								
189	579	CALCIUM PANTOTHENATE 50MG+VIT B12 15 MCG+FOLIC ACID 1.5MG+THIAMINE MONONITRATE 10MG+RIBOFLAVINE 10MG+PYRIDOXINE HCL 3 MG+NIACINAMIDE 100 MG+ASCORBIC ACID 150MG +BIOTIN 100MCG CAPSULES	20's								

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Break up of Landed Price

Note 1: The firms should indicate breakup prices at column 5 to 8 and 10 to 12 separately and working like "included" should not be substituted for the same as per specification laid down in relevant Pharmacopoeias.

Note 2: For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

*As per stated formulation /Combination is fixed but strength may vary

Sl. No	Drug code	Generic Name of the Medicines	Unit Size	Basic price Inclusive of incidental services	Bar coding charges	Packing and Forwarding Charges	Freight and insurance charges	Total landed prices	Rate of		Cen. Excise duty applicable (Y/N)
									CST %	VAT %	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
190	580	ginseng extract 42.5 mg, vitamin A 2500 IU, vitamin B1 1 mg, vitamin B2 1.5 mg, vitamin B6 1 mg, vitamin B12 1 mcg, vitamin C 50 mg, vitamin E 5 mg, vitamin D 200 IU, nicotinamide 10 mg, carbohydrates 0.1 g, folic acid 0.15 mg, ferrous fumarate 30 mg, copper 0.5 mg, potassium sulphate 2 mg, manganese 0.5 mg, magnesium sulphate 3 mg, zinc oxide 10 mg, calcium 75 mg, phosphate 58 mg, iodine 0.1 mg, protein 0.2 g, fat 0.38 g	10's								
191	581	CALCIUM CARBONATE 500 MG + CALCITRIOL 0.25 MCG + ZINC 7.5 MG	15's								
192	582	VITAMINS A,C,D,E,AND B COMPLEX AND MINERALS SYRUP	200 ML								
193	584	CALCIUM CITRATE MALATE 250 MG , VITAMIN D3 100 IU AND FOLINIC ACID 50 MCG TABLETS	30's								
194	586	METHYLCOBALAMIN 1500 MCG, L-CARTININE L-TARTRATE 500 MG, FOLIC ACID 1.5 MG TABLETS	10's								
195	587	APPETITE ENHANCER (PEPTONE, MINERALS, VITAMINS)SYRUP	300 ML								
196	588	VITAMIN E SOFTGEL CAPSULES 400 MG	10's								
197	590	VITAMIN A,B COMPLEX,D,E INJECTION	10 ML VIAL								
198	591	METHYLCOBALAMIN 500 MCG INJECTION	1 ML AMPU LE								
199	592	L-LYSINE + MULTIVITAMINS (VIT-B1,B2,B3,B5,B6) SYRUP	200 ML								

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015

Break up of Landed Price

Note 1: The firms should indicate breakup prices at column 5 to 8 and 10 to 12 separately and working like "included" should not be substituted for the same as per specification laid down in relevant Pharmacopoeias.

Note 2: For combination drugs which are not official in the Pharmacopoeias, the manufacturer will have to Provide the test Protocol.

*As per stated formulation /Combination is fixed but strength may vary

Sl. No	Drug code	Generic Name of the Medicines	Unit Size	Basic price Inclusive of incidental services	Bar coding charges	Packing and Forwarding Charges	Freight and insurance charges	Total landed prices	Rate of		Cen. Excise duty applicable (Y/N)
									CST %	VAT %	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
200	593	NICOTINAMIDE 200 MG+ FOLIC ACID 15 MG + CYANOCOBALAMIN 0.5 MCG INJECTION	10 ML								
201	594	GLUCOSE D POWDER	100 GM								
202	595	THIAMINE 100 MG+ PYRIDOXINE HCl 50 MG + CYANOCOBALAMIN 1000 MCG INJECTION	2 ML								
203	596	ZINC SULPHATE 20 MG/ ML ORAL SOLUTION	15 ML								
204	597	VITAMIN B6 TABLETS IP 5 MG	10's								
205	599	PREGABALIN TABLETS 75 MG	10's								

ANNEXURE – XIX

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA GURGAON(HR)								
TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT 13/07/2015								
Landed Price								
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total value (5x6) in figures
						In figures (in Rs.)	In words	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
1	14	Ibuprofen 400 mg+ Paracetamol 325 mg Tabs.	10's	200000				
2	15	Ibuprofen 200 mg Tabs.	10's	500000				
3	16	Ibuprofen 400 mg Tabs.	10's	100000				
4	25	Serratiopeptidase Tablets 10 mg	10's	105000				
5	53	Cefixime Oral Suspension IP 50 mg/5 ml	30 ml bottle	200000				
6	60	CEFOTAXIME SODIUM 250 MG & SULBACTAM SODIUM 125 MG INJECTION	VIAL & WFI	75000				
7	83	CIPROFLOXACIN 250 MG+ TINIDAZOLE 300 MG FILM COATED TABLETS	10's	96000				
8	89	CO-TRIMOXAZOLE TABLETS IP (160 MG + 800 MG)	10's	120000				
9	112	BECLOMETHASONE IP 0.025% w/w+ CLOTRIMAZOLE IP 1% w/w+ GENTAMYCIN IP 0.1% w/w CREAM	15 GM	2,70,000				
10	115	Calamine lotion 100 ml	100ml bottal	100000				
11	127	Povidone Iodine 5% Solution 100MI	100ml bottal	100000				
12	143	BIPHASIC INSULIN ASPART INJECTION IP 100 IU/ML (30:70)	VIAL	47000				
13	144	METFORMIN HYDROCHLORIDE SUSTAIN RELEASE TABLETS IP 1000 MG	10's	200000				
14	153	CISPLATIN INJECTION IP 10 MG	VIAL & WFI	100000				

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

**TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT
13/07/2015**

Landed Price

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total value (5x6) in figures
						In figures (in Rs.)	In words	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
15	165	CIPROFLOXACIN INJECTION IP 2MG/ML	100 ML	100000				
16	191	FAMOTIDINE TABLETS IP 20 MG	14's	485000				
17	192	FAMOTIDINE TABLETS IP 40 MG	14's	1010000				
18	194	Hyoscine Butyl Bromide film coated tablet 10 mg	10's	200000				
19	196	LACTOBACILLUS SPOROGENES 60 MILLION SPORES TABLETS	10's	243000				
20	201	METRONIDAZOLE 200 MG FILM COATED TABLETS	10'S	200000				
21	202	METRONIDAZOLE 400 MG FILM COATED TABLETS	10'S	500000				
22	208	ONDENSETRON INJECTION IP 2 mg/ml	2 ML	120000				
23	213	Pantoprazole 40mg/10ml Inj.	vial	200000				
24	216	RANITIDINE INJECTION IP 50 MG/ 2ML	2 ML	760000				
25	225	IRON HYDROXIDE POLYMALTOSE COMPLEX EQ TO ELEMENTAL IRON 50 MG+ FOLIC ACID 0.5 MG /5 ML SYRUP	200 ML	100000				
26	229	Haematinic Syrup of Iron , acid and Vitamin B12 100ml	100ml bottal	100000				
27	230	VITAMIN B COMPLEX (B1,B2,B6,B12) & VIT. C WITH ZINC 22.5 MG CAPSULES	10's	517000				
28	231	VITAMIN B1 10MG, B2 10 MG, NIACINAMIDE 45 MG, CALCIUM PANTOTHENATE 50 MG, B6 3 MG AND B12 15 MCG TABLETS	10's	1924000				
29	232	VITAMIN B-VOMPLEX Syrup NFI	200 ML	200000				
30	235	BUDESONIDE RESPULES 0.5 MG	2 ML	912000				
31	241	COUGH SYRUP DEXTROMETHORPHAN HBR10 mg+ CPM 4 MG /10	100 ML	185000				

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

**TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT
13/07/2015**

Landed Price

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total value (5x6) in figures
						In figures (in Rs.)	In words	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
		ML SYRUP						
32	244	THEOPHYLLINE 25.3 MG+ ETOPHYLLINE 84.6MG INJECTION 2 ML	2 ML	1746000				
33	255	SALBUTAMOL INHALATION IP 100 µg/ METERED DOSE	200 MD	182000				
34	256	salbutamol 2mg tablets	10x10	200000				
35	278	FRUSEMIDE INJECTION IP (10 MG/ ML)	2 ML	107000				
36	285	AMLODIPINE 5 MG + LISINOPRIL 5 MG TABLETS	15's	103000				
37	302	TRANEXAMIC ACID 500 MG/5 ML	5 ML AMPULE	210000				
38	306	PRIMAQUINE TABLETS IP 15 MG	7's	120000				
39	323	FLUNARZINE TABLETS 10MG	10's	200000				
40	324	FLUNARZINE TABLETS 5MG	10's	95000				
41	329	PREDNISOLONE TABLETS IP 5 MG	15's	1573000				
42	331	THYROXINE SODIUM TABLETS IP 50 µg	10's	210000				
43	333	dexamethazole 0.5 mg Tablets	10x10	200000				
44	334	DEXAMETHASONE INJECTION IP 4 MG/ML	2 ML	1112000				
45	338	ATROPINE SULPHATE INJECTION IP 0.6MG/ ML	1 ML	100000				
46	341	CARBOXY METHYL CELLULOSE EYE DROPS IP 0.5% w/v	10 ML	100000				
47	344	Ciprofloxacin 0.3% w/V Eye drops	5ml	500000				
48	345	gentamycin 0.3 % w/V eye drops	5ml	500000				
49	356	LIGNOCAINE INJECTION IP 2% w/v	20 ML VIAL	200000				
50	357	Ligncaine 1% + adrenaline 2% W/V inj.	30 ml vial	100000				
51	358	Propafol 10mg/ ml Inj	10ml vial	100000				
52	359	TETANUS VACCINE (Adsorbed) IP	AMP 0.5 ML	1160000				
53	361	OXYTOCIN INJECTION IP 5 UNITS/ML	1 ML	1000000				
54	362	BIPHASIC ISOPHANE	10 ML	340000				

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

**TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT
13/07/2015**

Landed Price								
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total value (5x6) in figures
						In figures (in Rs.)	In words	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
		INSULIN INJECTION IP 40 IU/ML (50:50)	VIAL					
55	366	GLIPIZIDE 5 MG + METFORMIN HYDROCHLORIDE 500 MG TABLETS	10's	1309000				
56	368	GLICLAZIDE TABLETS SR 60 MG	10's	55000				
57	369	ACARBOSE TABLETS IP 50 MG	10's	46000				
58	370	NEUTRAL PROTAMINATED HAGEDORN INJECTION 40 IU	10 ML VIAL	40000				
59	372	METFORMIN HYDROCHLORIDE TABLETS IP PROLONG RELEASE 500 MG	10's	100000				
60	373	ARTESUNATE INJECTION 60 MG	1 ML	99000				
61	374	ARTEMETHER 80 MG + LUMEFANTRINE 480 MG SR TABLETS	6's	91000				
62	375	QUININE TABLETS IP 300 MG FILM COATED TABLETS	10's	44000				
63	377	CLINDAMYCIN CAPSULES IP 300 MG	10's	22000				
64	378	EACH KIT CONTAIN RIFAMPICIN TABLET IP 450MG, ISONIAZIDE TABLET IP 300MG ETHAMBUTOL TABLET IP 800MG AND PYRAZINAMIDE TABLETS IP 750MG	1's	655000				
65	379	RIFAMPICIN and ISONIAZIDE TABLETS IP (450 MG+300 MG)	10's	144000				
66	382	LINEZOLID TABLETS IP 600 MG	10's	95000				
67	387	TERBINAFINE 250 MG TABLETS	7's	206000				
68	388	EACH KIT CONTAIN RIFAMPICIN TABLET IP 450MG, ISONIAZIDE TABLET IP 300MG and ETHAMBUTOL TABLET IP 800MG	1's	484000				

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

**TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT
13/07/2015**

Landed Price

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total value (5x6) in figures
						In figures (in Rs.)	In words	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
69	389	PENICILLIN G 400000 IU TABLETS	6's	684000				
70	390	ETHAMBUTOL TABLETS IP 800 MG	10's	129000				
71	391	MOXIFLOXACIN TABLETS 400 MG	5's	134000				
72	392	GRISEOFULVIN TABLETS IP 250 MG	10's	220000				
73	393	ACICLOVIR DISPERSIBLE TABLETS IP 800 MG	5's	47000				
74	394	PYRANTEL PAMOATE ORAL SUSPENSION IP 250 MG/10 ML	10 ML	237000				
75	396	AMPHOTERICIN B INJECTION IP, 50MG/ML	20 ML	4000				
76	397	OXYTETRACYCLINE CAPSULES IP 250 MG	8's	486000				
77	398	RIFAMPICIN TABLETS IP 450 MG	10's	28000				
78	399	RIFAMPICIN, ISONIAZIDE and PYRAZINAMIDE TABLETS IP (120MG+50MG+300MG)	10's	76000				
79	403	CLINDAMYCIN INJ IP 300 MG/2 ML	2 ML	38000				
80	404	LINEZOLID INFUSION 600 MG/300 ML	300 ML	577000				
81	406	ACICLOVIR INTRAVENOUS INFUSION IP 500 MG/VIAL	VIAL	98000				
82	407	IVERMECTIN TABLETS 12 MG	10's	120000				
83	408	BENZYL PENICILLIN INJECTION IP 0.6 MILLION UNITS	VIAL	120000				
84	409	BENZYL PENICILLIN INJECTION IP 1.2 MILLION UNITS	VIAL	120000				
85	410	TRASTUZUMAB INJECTION 440 MG with WFI	1's	1000				
86	411	BEVACIZUMAB INJECTION 25 MG	1's	1000				
87	412	AZATHIOPRINE TABLETS IP 50 MG	10's	57000				
88	413	METHOTREXATE TABLETS IP 7.5 MG	10's	35000				
89	415	GLYCERYL TRINITRATE TABLETS IP 250 µg	25's	194000				

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

**TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT
13/07/2015**

Landed Price

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total value (5x6) in figures
						In figures (in Rs.)	In words	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
90	416	PRAZOSIN TABLETS IP 5 MG	15's	137000				
91	419	HEPARIN SODIUM 50 IU/20 GM OINTMENT	20 GM	139000				
92	420	ATORVASTATIN 10 MG+ CLOPIDOGREL 75 MG CAPSULES	10's	100000				
93	421	NEBIVOLOL TABLETS IP 5 MG	10's	234000				
94	423	BISOPROLOL TABLETS 5 MG	10's	121000				
95	424	CARVEDILOL TABLETS IP 3.125 MG	10's	258000				
96	425	DILTIAZEM TABLETS SR 90 MG	10's	100000				
97	426	ACENOCOUMAROL TABLETS 2 MG	30's	26000				
98	427	S-AMLODIPINE TABLETS IP 2.5 MG	10's	366000				
99	431	RAMIPRIL and HYDROCLORTHIAZIDE TABLETS IP (5MG+12.5 MG)	10's	60000				
100	433	ISOSORBIDE MONONITRATE TABLETS IP 30 MG	30's	42000				
101	438	INDAPAMIDE TABLETS IP 1.5 MG	10's	50000				
102	440	METOPROLOL 50 MG + AMLODIPINE 5 MG TABLETS	7's	400000				
103	441	LOSARTAN 50 MG+ AMLODIPINE 5 MG TABLETS	10's	278000				
104	442	FENOFIBRATE CAPSULES IP 150 MG	10's	42000				
105	443	ISOSORBIDE DINITRATE TABLETS IP 5 MG	50's	122000				
106	444	ENALAPRIL 10 MG + HYDROCLORTHIAZIDE 25 MG TABLETS	30's	24000				
107	446	AMLODIPINE 5 MG + HYDROCHLOROTHIAZIDE 12.5 MG TABLETS	10's	173000				
108	447	MOXONIDINE TABLETS 0.3 MG	10's	55000				
109	448	AMLODIPINE 5 MG+ RAMIPRIL 5 MG TABLETS	10's	50000				
110	449	SPIRONOLACTONE	15's	67000				

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

**TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT
13/07/2015**

Landed Price								
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total value (5x6) in figures
						In figures (in Rs.)	In words	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
		TABLETS IP 25 MG						
111	450	LABETALOL TABLETS IP 100 MG	10's	25000				
112	452	WARFARIN TABLETS IP 5 MG	10's	76000				
113	453	BISOPROLOL 5 MG+ HYDROCHLOROTHIAZIDE 6.25 MG TABLETS	10's	22000				
114	454	VALSARTAN TABLETS IP 80 MG	10's	30000				
115	455	VERAPAMIL TABLETS IP 80 MG	10's	120000				
116	457	TORASEMIDE TABLETS 20 MG	10's	210000				
117	461	BETAMETHASONE VALERAT 0.1 % w/w + NEOMYCIN SULFATE 0.5 % w/w CREAM	20 GM	1513000				
118	462	BETAMETHASONE VALERATE and CLIOQUINOL CREAM BP (0.12w/w+3%w/w)	30 GM	701000				
119	464	DICYCLOMINE 10 MG + PARACETAMOL 325 MG + TRAMADOL 50 MG CAPSULES	10's	1287000				
120	468	BACILLUS CLAUSII SPORES ORAL SUSPENSION 2 Billion/ 5 ML	5 ML	425000				
121	469	HEPATIC PROTECTORS SYRUP	200 ML	640000				
122	470	PEPSIN 10 MG+ DIASTASE 50 MG ORAL LIQUID /5 ML	200 ML	234000				
123	471	OXETACAINE 10 MG+ ALUMINIUM 291 MG + MAGNESIUM 98 MG /5 ML GEL	200 ML	211000				
124	472	DOMPERIDONE 30 MG+ ESOMEPRAZOLE 40 MG CAPSULE	10's	133000				
125	473	LEVOSULPIRIDE 75 MG+ PANTOPRAZOLE 40 MG CAPSULE	10's	56000				
126	476	LIQUID PARAFFIN 1.25 ML+ MILK OF MAGNESIA 3.75ML+ SODIUM PICOSULPHATE 3.33MG /5ML EMULSION	200 ML	137000				

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

**TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT
13/07/2015**

Landed Price

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total value (5x6) in figures
						In figures (in Rs.)	In words	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
127	477	CLIDINIUM 2.5 MG+ CHLORDIAZEPOXIDE 5 MG FILM COATED TABLETS	15's	191000				
128	479	TRICHOLINE CITRATE 550 MG + SORBITOL 7.15 MG SYRUP/5 ML	200 ML	77000				
129	480	LEVOSULPIRIDE 75 MG+ ESOMEPRAZOLE 40 MG CAPSULES	10's	69000				
130	481	RIFAXIMIN TABLETS BP 40 MG	10's	48000				
131	486	PANCREATIN 170 MG+ DIMETHICONE 80 MG TABLETS	10's	200000				
132	487	DICYCLOMINE 10 MG + DIMETHICONE 40 MG /5 ML SUSPENSION	30 ML	172000				
133	488	LANSOPRAZOLE CAPSULES IP 15 MG	10's	85000				
134	489	SULFASALAZINE TABLETS BP 1000 MG ENTERIC COATED	10's	73000				
135	490	SIMETHICONE 40 MG DROPS	15 ML	120000				
136	492	SULFASALAZINE TABLETS BP 500 MG ENTERIC COATED	10's	73000				
137	493	ISPAGHULA HUSK IP 50 GM	50 GM	47000				
138	494	ISPAGHULA HUSK IP 100 GM	100 GM	47000				
139	495	FERROUS AMMONIUM CITRATE 160 MG + CYANO COBALAMINE 7.5 MCG + FOLIC ACID 0.5 MG/15ML SYRUP	200 ML	480000				
140	496	DYDROGESTERONE TABLETS IP 10 MG	10's	101000				
141	498	FERROUS ASCORBATE 100MG WITH FOLIC ACID 1.5MG TABLETS	10's	253000				
142	500	LEVO-THYROXINE TABLETS IP 100 MCG	100's in A Bottle	269000				
143	501	BETAMETHASONE SODIUM PHOSPHATE TABLETS IP 0.5 MG	20's	2425000				
144	503	METHYLPREDNISOLONE SODIUM SUCCINATE	VIAL & WFI	50000				

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

**TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT
13/07/2015**

Landed Price								
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total value (5x6) in figures
						In figures (in Rs.)	In words	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
		INJECTION 1000 MG PER VIAL						
145	504	NANDROLONE DECANOATE INJECTION IP 25MG/ML	2 ML	57000				
146	505	CARBIMAZOLE TABLETS IP 10 MG	100's in Bottle	19000				
147	506	LEVO-THYROXINE TABLETS IP 50 MCG	100's in Bottle	269000				
148	507	CARBIMAZOLE TABLETS IP 5 MG	10's	120000				
149	514	CHYMOTRYPSIN + TRYPSIN (1:6)ENTERIC COATED TABLETS 100K AU	20's	65000				
150	519	KETOROLAC TABLETS DT 10 MG	10's	167000				
151	520	MEFENAMIC ACID 500 MG+ PARACETAMOL 325 MG TABLETS	10's	140000				
152	521	TRAMADOL TABLETS SR 100 MG	10's	50000				
153	522	ALFACALCIDOL SOFT GELATIN CAPSULES 0.25 MCG	10's	100000				
154	523	NAPROXEN TABLETS IP 500 MG	15's	49000				
155	524	LIDOCAINE INJECTION IP 2 %W/V	30 ML VIAL	96000				
156	526	CHLORPHENIRAMINE 4 MG+ CODEINE 10 MG/5 ML SYRUP	100 ML	1675000				
157	527	AMMONIUM CHLORIDE 50 MG+ CHLORPHENIRAMINE MALETAE 2.5 MG+ DEXTROMETHORPHAN 5 MG+ GUAIFENESIN 50 MG / 5ML SYRUP	100 ML	258000				
158	529	LEVOSALBUTAMOL 1.25 MCG+ IPRATROPIUM 500 MCG RESPULES/2.5ML	2.5 ML	1360000				
159	530	FORMOTERAL 6 MG+ BUDESONIDE 200 MG ROTACAP	30's	89000				
160	532	SALMETEROL 50 MG+ FLUTICASONE 250 MG ROTACAP	30's	47000				
161	534	SALBUTAMOL 200 MCG +	30's	357000				

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

**TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT
13/07/2015**

Landed Price								
Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total value (5x6) in figures
						In figures (in Rs.)	In words	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
		BECLOMETHASONE 100 MCG ROTACAP						
162	535	TERBUTALINE 2.5 MG + BROMHEXINE 8 MG /10 ML SYRUP	100 ML	192000				
163	536	PROMETHAZINE 1.5 MG + PHOLCODINE CITRATE 1.5 MG /5ML LINCTUS	60 ML	151000				
164	537	SALBUTAMOL 1 MG+ AMBROXOL HYDROCHLORIDE 15 MG/5 ML SYRUP	100 ML	548000				
165	538	THEOPHYLLINE TABLETS 400 MG	10's	91000				
166	540	LEVBUTEROL 1.25 MG+ BUDESONIDE 1MG REPSULE	2 ML	209000				
167	543	MENTHOL CINNAMON and PINE OIL SOFT CAPSULES	10's	128000				
168	544	FLUTICASONE PROPIONATE RESPULE 0.5 MG/2ML	2 ML	117000				
169	555	DOXOFYLLINE TABLETS IP 400 MG	10's	275000				
170	556	MONTELUKAST 10 MG + FEXOFENADINE 120 MG TABLETS	10's	147000				
171	557	TIOTROPIUM ROTOCAP 18 MCG	15's	23000				
172	558	FLUTICASONE 50 MCG+ AZELASTINE 140 MCG NASAL SPRAY	120MD	13000				
173	559	SALBUTAMOL 2MG + THEOPHYLLINE 100 MG TABLETS	30's	285000				
174	560	FLUTICASONE PROPIONATE 50 MCG PER PUFF NASAL SPRAY	120 MD	16000				
175	561	LEVOSALBUTAMOL 1 MG/5ML SYRUP	100 ML	137000				
176	563	OXYMETAZOLINE 0.5 MG /ML NASAL DROPS	10 ML	100000				
177	564	FORMOTEROL 12 MG + TIOTROPIUM 18 MG ROTOCAP	15's	19000				
178	565	CICLESONIDE 400 MCG+ FORMOTEROL 12 MCG + TIOTROPIUM 18 MCG ROTOCAP	15's	6000				

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

**TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT
13/07/2015**

Landed Price

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total value (5x6) in figures
						In figures (in Rs.)	In words	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
179	566	IPRATROPIUM 250 MCG/ML I:SOLUTION	15 ML	26000				
180	567	SALBUTAMOL 100 MCG + IPRATROPIUM 20 MCG /PUFF INHALER	100 MD	7000				
181	568	SALMETEROL 50 MCG+ FLUTICASONE PROPIONATE 250 MCG /PUFF INHALER	100 MD	28000				
182	571	TAMSULOSIN 0.4 MG + DUTASTERIDE 0.5 MG TABLETS	15's	44000				
183	572	COMBINATIONS WITH TETANUS COMPONENT (DIPHTHERIA, TETANUS, PERTUSSIS, POLIOMYELITIS AND HAEMOPHILUS INFLUENZA) INJECTION	0.5 ML	40000				
184	573	MONOCLONAL ANTI-D GAMAGLOBULIN INJECTION 300 MCG	1 ML with WFI	11000				
185	575	VACCINE VARICELLA INJECTION	0.5 ML	15000				
186	576	VACCINE HEPATITIS A INJECTION 80 IU	5 ML	13000				
187	577	VACCINE STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE INJECTION 0.5 ML	0.5 ML	11000				
188	578	VACCINE ROTA VIRUS LIVE ORAL	1 ML	20000				
189	579	CALCIUM PANTOTHENATE 50MG+VIT B12 15 MCG+FOLIC ACID 1.5MG+THIAMINE MONONITRATE 10MG+RIBOFLAVINE 10MG+PYRIDOXINE HCL 3 MG+NIACINAMIDE 100 MG+ASCORBIC ACID 150MG +BIOTIN 100MCG CAPSULES	20's	2971000				
190	580	ginseng extract 42.5 mg, vitamin A 2500 IU, vitamin B1 1 mg, vitamin B2 1.5 mg, vitamin B6 1 mg, vitamin B12 1 mcg, vitamin C 50 mg,	10's	451000				

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

**TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT
13/07/2015**

Landed Price

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total value (5x6) in figures
						In figures (in Rs.)	In words	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
		vitamin E 5 mg, vitamin D 200 IU, nicotinamide 10 mg, carbohydrates 0.1 g, folic acid 0.15 mg, ferrous fumarate 30 mg, copper 0.5 mg, potassium sulphate 2 mg, manganese 0.5 mg, magnesium sulphate 3 mg, zinc oxide 10 mg, calcium 75 mg, phosphate 58 mg, iodine 0.1 mg, protein 0.2 g, fat 0.38 g						
191	581	CALCIUM CARBONATE 500 MG + CALCITRIOL 0.25 MCG + ZINC 7.5 MG	15's	113000				
192	582	VITAMINS A,C,D,E,AND B COMPLEX AND MINERALS SYRUP	200 ML	184000				
193	584	CALCIUM CITRATE MALATE 250 MG , VITAMIN D3 100 IU AND FOLINIC ACID 50 MCG TABLETS	30's	171000				
194	586	METHYLCOBALAMIN 1500 MCG, L- CARTININE L- TARTRATE 500 MG, FOLIC ACID 1.5 MG TABLETS	10's	100000				
195	587	APPETITE ENHANCER (PEPTONE, MINERALS, VITAMINS)SYRUP	300 ML	172000				
196	588	VITAMIN E SOFTGEL CAPSULES 400 MG	10's	483000				
197	590	VITAMIN A,B COMPLEX,D,E INJECTION	10 ML VIAL	498000				
198	591	METHYLCOBALAMIN 500 MCG INJECTION	1 ML AMPULE	115000				
199	592	L-LYSINE + MULTIVITAMINS (VIT-B1,B2,B3,B5,B6) SYRUP	200 ML	207000				
200	593	NICOTINAMIDE 200 MG+ FOLIC ACID 15 MG + CYANOCOBALAMIN 0.5 MCG INJECTION	10 ML	109000				
201	594	GLUCOSE D POWDER	100 GM	22000				
202	595	THIAMINE 100 MG+ PYRIDOXINE HCl 50 MG + CYANOCOBALAMIN 1000 MCG INJECTION	2 ML	602000				
203	596	ZINC SULPHATE 20 MG/	15 ML	40000				

**BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKING OF INDIA
GURGAON(HR)**

**TENDER FOR THE SUPPLY OF MEDICINES REFERENCE BPPI/DRUG/025 DT
13/07/2015**

Landed Price

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Approx. tender Quantity in units	Manufacturing capacity per year	Rate per unit Landed Price (rate quoted should be inclusive of all but exclusive of CST/VAT and central excise duty)		Total value (5x6) in figures
						In figures (in Rs.)	In words	
(1)	(2)	(3)	(4)	(5)	(6)	(7)		(8)
		ML ORAL SOLUTION						
204	597	VITAMIN B6 TABLETS IP 5 MG	10's	147000				
205	599	PREGABALIN TABLETS 75 MG	10's	120000				